Form 10-Q
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
|
|
|
þ |
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended March 31, 2009
OR
|
|
|
o |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to .
COMMISSION FILE NUMBER: 0-19271
IDEXX LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
|
|
|
DELAWARE
|
|
01-0393723 |
(State or other jurisdiction of incorporation
|
|
(IRS Employer Identification No.) |
or organization) |
|
|
|
|
|
ONE IDEXX DRIVE, WESTBROOK, MAINE
|
|
04092 |
(Address of principal executive offices)
|
|
(ZIP Code) |
207-556-0300
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months
(or for such shorter period that the registrant was required to submit and post such files). Yes
o No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large
accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the
Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer þ
|
|
Accelerated filer o
|
|
Non-accelerated filer o
|
|
Smaller reporting company o |
|
|
|
|
(Do not check if a smaller reporting company) |
|
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of
the Exchange Act). Yes o No þ
Indicate the number of shares outstanding of each of the issuers classes of common stock, as
of the latest practicable date. The number of shares outstanding of the registrants Common Stock,
$0.10 par value, was 59,013,088 on April 20, 2009.
IDEXX LABORATORIES, INC.
Quarterly Report on Form 10-Q
Table of Contents
2
PART I FINANCIAL INFORMATION
Item 1. Financial Statements.
IDEXX LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except per share amounts)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
December 31, |
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
ASSETS |
|
|
|
|
|
|
|
|
Current Assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
86,295 |
|
|
$ |
78,868 |
|
Accounts receivable, less reserves of $2,124 in 2009 and $2,093 in 2008 |
|
|
115,253 |
|
|
|
111,498 |
|
Inventories |
|
|
123,575 |
|
|
|
115,926 |
|
Deferred income tax assets, net |
|
|
20,915 |
|
|
|
21,477 |
|
Other current assets |
|
|
21,745 |
|
|
|
28,121 |
|
|
|
|
|
|
|
|
Total current assets |
|
|
367,783 |
|
|
|
355,890 |
|
Property and equipment, net |
|
|
186,708 |
|
|
|
189,646 |
|
|
Goodwill and other intangible assets, net |
|
|
200,748 |
|
|
|
207,095 |
|
Other long-term assets, net |
|
|
15,265 |
|
|
|
12,806 |
|
|
|
|
|
|
|
|
|
|
|
216,013 |
|
|
|
219,901 |
|
|
|
|
|
|
|
|
TOTAL ASSETS |
|
$ |
770,504 |
|
|
$ |
765,437 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY |
|
|
|
|
|
|
|
|
Current Liabilities: |
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
23,541 |
|
|
$ |
28,006 |
|
Accrued expenses |
|
|
29,482 |
|
|
|
32,857 |
|
Accrued employee compensation and related expenses |
|
|
28,051 |
|
|
|
43,252 |
|
Accrued taxes |
|
|
17,751 |
|
|
|
13,324 |
|
Accrued customer programs |
|
|
16,193 |
|
|
|
15,183 |
|
Short-term debt |
|
|
165,517 |
|
|
|
150,620 |
|
Current portion of long-term debt |
|
|
777 |
|
|
|
765 |
|
Deferred revenue |
|
|
10,831 |
|
|
|
11,285 |
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
292,143 |
|
|
|
295,292 |
|
Long-term Liabilities: |
|
|
|
|
|
|
|
|
Deferred tax liabilities |
|
|
12,339 |
|
|
|
11,933 |
|
Long-term debt, net of current portion |
|
|
4,896 |
|
|
|
5,094 |
|
Deferred revenue |
|
|
3,822 |
|
|
|
3,787 |
|
Other long-term liabilities |
|
|
11,476 |
|
|
|
11,137 |
|
|
|
|
|
|
|
|
Total long-term liabilities |
|
|
32,533 |
|
|
|
31,951 |
|
|
|
|
|
|
|
|
|
|
Commitments and Contingencies (Note 12) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stockholders Equity: |
|
|
|
|
|
|
|
|
Common stock, $0.10 par value: Authorized: 120,000 shares;
Issued: 95,630 and 95,387 shares in 2009 and 2008, respectively |
|
|
9,563 |
|
|
|
9,539 |
|
Additional paid-in capital |
|
|
553,446 |
|
|
|
547,692 |
|
Deferred stock units: Outstanding: 113 and 102 units in 2009 and 2008,
respectively |
|
|
4,146 |
|
|
|
3,647 |
|
Retained earnings |
|
|
728,102 |
|
|
|
702,031 |
|
Accumulated other comprehensive income (loss) |
|
|
(2,981 |
) |
|
|
5,675 |
|
Treasury stock, at cost: 36,662 and 36,164 shares in 2009 and 2008, respectively |
|
|
(846,448 |
) |
|
|
(830,390 |
) |
|
|
|
|
|
|
|
Total stockholders equity |
|
|
445,828 |
|
|
|
438,194 |
|
|
|
|
|
|
|
|
TOTAL LIABILITIES AND STOCKHOLDERS EQUITY |
|
$ |
770,504 |
|
|
$ |
765,437 |
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
3
IDEXX LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended |
|
|
|
March 31, |
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
Revenue: |
|
|
|
|
|
|
|
|
Product revenue |
|
$ |
155,895 |
|
|
$ |
168,990 |
|
Service revenue |
|
|
80,560 |
|
|
|
80,084 |
|
|
|
|
|
|
|
|
|
|
|
236,455 |
|
|
|
249,074 |
|
Cost of Revenue: |
|
|
|
|
|
|
|
|
Cost of product revenue |
|
|
59,267 |
|
|
|
64,541 |
|
Cost of service revenue |
|
|
52,755 |
|
|
|
54,697 |
|
|
|
|
|
|
|
|
|
|
|
112,022 |
|
|
|
119,238 |
|
|
|
|
|
|
|
|
Gross profit |
|
|
124,433 |
|
|
|
129,836 |
|
|
|
|
|
|
|
|
|
|
Expenses: |
|
|
|
|
|
|
|
|
Sales and marketing |
|
|
40,985 |
|
|
|
44,001 |
|
General and administrative |
|
|
29,068 |
|
|
|
29,821 |
|
Research and development |
|
|
15,939 |
|
|
|
17,295 |
|
|
|
|
|
|
|
|
Income from operations |
|
|
38,441 |
|
|
|
38,719 |
|
Interest expense |
|
|
(640 |
) |
|
|
(1,031 |
) |
Interest income |
|
|
244 |
|
|
|
546 |
|
|
|
|
|
|
|
|
Income before provision for income taxes |
|
|
38,045 |
|
|
|
38,234 |
|
Provision for income taxes |
|
|
11,974 |
|
|
|
10,683 |
|
|
|
|
|
|
|
|
Net income |
|
$ |
26,071 |
|
|
$ |
27,551 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings per Share: |
|
|
|
|
|
|
|
|
Basic |
|
$ |
0.44 |
|
|
$ |
0.45 |
|
|
|
|
|
|
|
|
Diluted |
|
$ |
0.43 |
|
|
$ |
0.43 |
|
|
|
|
|
|
|
|
Weighted Average Shares Outstanding: |
|
|
|
|
|
|
|
|
Basic |
|
|
59,172 |
|
|
|
60,865 |
|
|
|
|
|
|
|
|
Diluted |
|
|
60,606 |
|
|
|
63,558 |
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
4
IDEXX LABORATORIES, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
(Unaudited)
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended |
|
|
|
March 31, |
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
Cash Flows from Operating Activities: |
|
|
|
|
|
|
|
|
Net income |
|
$ |
26,071 |
|
|
$ |
27,551 |
|
Adjustments to reconcile net income to net cash provided (used) by operating activities: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
13,047 |
|
|
|
11,395 |
|
Decrease in deferred compensation expense |
|
|
(100 |
) |
|
|
(131 |
) |
Provision for uncollectible accounts |
|
|
246 |
|
|
|
523 |
|
Provision for (benefit of) deferred income taxes |
|
|
1,465 |
|
|
|
(999 |
) |
Share-based compensation expense |
|
|
2,930 |
|
|
|
2,878 |
|
Tax benefit from exercises of stock options and vesting of restricted stock units |
|
|
(161 |
) |
|
|
(2,384 |
) |
Changes in assets and liabilities, net of acquisitions: |
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(6,072 |
) |
|
|
(13,543 |
) |
Inventories |
|
|
(8,067 |
) |
|
|
(477 |
) |
Other assets |
|
|
179 |
|
|
|
(530 |
) |
Accounts payable |
|
|
(4,315 |
) |
|
|
(7,539 |
) |
Accrued liabilities |
|
|
(12,394 |
) |
|
|
(19,200 |
) |
Deferred revenue |
|
|
(205 |
) |
|
|
(333 |
) |
|
|
|
|
|
|
|
Net cash provided (used) by operating activities |
|
|
12,624 |
|
|
|
(2,789 |
) |
Cash Flows from Investing Activities: |
|
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
(9,114 |
) |
|
|
(17,049 |
) |
Proceeds from disposition of pharmaceutical product lines |
|
|
1,377 |
|
|
|
|
|
Proceeds from sale of property and equipment |
|
|
1,046 |
|
|
|
|
|
Acquisitions of equipment leased to customers |
|
|
(188 |
) |
|
|
(226 |
) |
Acquisitions of intangible assets and businesses, net of cash acquired |
|
|
|
|
|
|
(7,533 |
) |
|
|
|
|
|
|
|
Net cash used by investing activities |
|
|
(6,879 |
) |
|
|
(24,808 |
) |
Cash Flows from Financing Activities: |
|
|
|
|
|
|
|
|
Borrowings on revolving credit facilities, net |
|
|
15,019 |
|
|
|
67,942 |
|
Payment of other notes payable |
|
|
(190 |
) |
|
|
(177 |
) |
Purchase of treasury stock |
|
|
(14,986 |
) |
|
|
(51,355 |
) |
Proceeds from exercises of stock options and employee stock purchase plans |
|
|
3,281 |
|
|
|
5,974 |
|
Tax benefit from exercises of stock options and vesting of restricted stock units |
|
|
161 |
|
|
|
2,384 |
|
|
|
|
|
|
|
|
Net cash provided by financing activities |
|
|
3,285 |
|
|
|
24,768 |
|
Net effect of exchange rates on cash |
|
|
(1,603 |
) |
|
|
2,689 |
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents |
|
|
7,427 |
|
|
|
(140 |
) |
Cash and cash equivalents at beginning of period |
|
|
78,868 |
|
|
|
60,360 |
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period |
|
$ |
86,295 |
|
|
$ |
60,220 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental Disclosures of Cash Flow Information: |
|
|
|
|
|
|
|
|
Interest paid |
|
$ |
1,105 |
|
|
$ |
1,182 |
|
Income taxes paid |
|
$ |
3,337 |
|
|
$ |
15,343 |
|
The accompanying notes are an integral part of these condensed consolidated financial statements.
5
IDEXX LABORATORIES, INC. AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1. BASIS OF PRESENTATION AND PRINCIPLES OF CONSOLIDATION
The accompanying unaudited, condensed consolidated financial statements of IDEXX Laboratories,
Inc. (IDEXX, the Company, we or our) have been prepared in accordance with accounting
principles generally accepted in the United States of America (U.S. GAAP) for interim financial
information and with the requirements of Regulation S-X, Rule 10-01 for financial statements
required to be filed as a part of Form 10-Q.
The accompanying unaudited, condensed consolidated financial statements include the accounts
of IDEXX Laboratories, Inc. and our wholly-owned and majority-owned subsidiaries, and all other
entities in which we have a variable interest and are determined to be the primary beneficiary. All
material intercompany transactions and balances have been eliminated in consolidation.
The accompanying unaudited, condensed consolidated financial statements reflect, in the
opinion of our management, all adjustments necessary for a fair statement of our financial position
and results of operations. The condensed balance sheet data at December 31, 2008 was derived from
audited financial statements, but does not include all disclosures required by U.S. GAAP. The
results of operations for the three months ended March 31, 2009 are not necessarily indicative of
the results to be expected for the full year or any future period. These unaudited, condensed
consolidated financial statements should be read in conjunction with this Quarterly Report on Form
10-Q for the three months ended March 31, 2009, and our Annual Report on Form 10-K for the year
ended December 31, 2008 filed with the Securities and Exchange Commission.
Certain reclassifications have been made to the prior year condensed consolidated financial
statements to conform to the current year presentation. Reclassifications had no material impact on
previously reported results of operations or financial position.
NOTE 2. ACCOUNTING POLICIES
Significant Accounting Policies
The significant accounting policies used in preparation of these condensed consolidated
financial statements for the three months ended March 31, 2009 are consistent with those discussed
in Note 3 to the consolidated financial statements in our Annual Report on Form 10-K for the year
ended December 31, 2008.
Recent Accounting Pronouncements
We adopted the provisions of Financial Accounting Standards Board (FASB) Statement of
Financial Accounting Standard (SFAS) No. 141(R), Business Combinations (SFAS No. 141(R)),
which revised SFAS No. 141, Business Combinations, on January 1, 2009. SFAS No. 141(R)
establishes principles and requirements for how an acquirer recognizes and measures in its
financial statements the identifiable assets acquired, the liabilities assumed, any noncontrolling
interest in the acquiree and the goodwill acquired. SFAS No. 141(R) also establishes disclosure
requirements, which will enable users to evaluate the nature and financial effects of business
combinations. Among other things, SFAS No. 141(R) expands the definitions of a business and business
combination, requires recognition of contingent consideration at fair value on the acquisition date
and requires acquisition-related transaction costs to be expensed as incurred. As the provisions of
SFAS No. 141(R) are applied prospectively, there was no impact of adoption on our financial
position, results of operations, or cash flows.
We adopted the provisions SFAS No. 157, Fair Value Measurements (SFAS No. 157) for
nonfinancial assets and nonfinancial liabilities, which were previously deferred by FASB Staff
Position (FSP) No. SFAS 157-2, Effective Date of FASB Statement No. 157 (FSP No. SFAS 157-2),
on January 1, 2009. SFAS No. 157 establishes a framework for measuring fair value and expands
financial statement disclosures about fair value measurements. Items to which the deferral under
FSP No. SFAS 157-2 applied include nonrecurring fair value measurements of nonfinancial assets and
nonfinancial liabilities, or recurring fair value measurements of nonfinancial assets and
nonfinancial liabilities, which are not disclosed at fair value in the consolidated financial
statements. We did not have nonfinancial assets or
nonfinancial liabilities covered by the provisions of SFAS No. 157 which required remeasurement upon adoption
or during the three months ended March 31, 2009, and therefore there was no impact of adoption on
our financial position, results of operations, or cash flows.
6
We adopted the provisions of SFAS No. 160, Noncontrolling Interests in Consolidated Financial
Statements (SFAS No. 160), on January 1, 2009. SFAS No. 160 establishes accounting and reporting
standards for ownership interests in subsidiaries held by parties other than the parent, the amount
of consolidated net income attributable to the parent and to the noncontrolling interest, changes
in a parents ownership interest and the valuation of retained noncontrolling equity investments
when a subsidiary is deconsolidated. SFAS No. 160 also establishes reporting requirements that
provide enhanced disclosures that clearly identify and distinguish between the interests of the
parent and the interests of the noncontrolling owners. There was no impact of adoption of SFAS No.
160 on our financial position, results of operations or cash flows.
We adopted the provisions of SFAS No. 161, Disclosures about Derivative Instruments and
Hedging Activities an amendment of SFAS No. 133 (SFAS No. 161), on January 1, 2009. SFAS
No. 161 changes the disclosure requirements for derivative instruments and hedging activities. This
standard requires enhanced disclosures about how and why an entity uses derivative instruments, how
instruments are accounted for under SFAS No. 133, Accounting for Derivative Instruments and
Hedging Activities (SFAS No. 133), and how derivatives and hedging activities affect an entitys
financial position, financial performance and cash flows. The adoption of SFAS No. 161 required
additional disclosure only, and therefore did not have an impact on our financial position, results
of operations, or cash flows. See Note 16 for a discussion of our derivative instruments and
hedging activities.
We adopted the provisions of FSP Financial Accounting Standard (FAS)
142-3, Determination of the Useful Life of Intangible Assets (FSP FAS 142-3), on January 1,
2009. FSP FAS 142-3 amends SFAS No. 142, Goodwill and Other Intangible Assets (SFAS No. 142) to
improve the consistency between the useful life of a recognized intangible asset under SFAS No. 142
and the period of expected cash flows used to measure the fair value of the asset under SFAS No.
141(R) and other U.S. GAAP. As the provisions of FSP FAS 142-3 are applied prospectively, there was
no impact of adoption on our financial position, results of operations, or cash flows.
NOTE 3. SHARE-BASED COMPENSATION
For the three months ended March 31, 2009, share-based compensation expense included $2.7
million for options, restricted stock units and deferred stock units with vesting conditions and
$0.2 million for employee stock purchase rights. Expense for deferred stock units issued under our
Director Deferred Compensation Plan without vesting conditions of $0.1 million for the three months
ended March 31, 2009 and 2008 has been excluded from share-based compensation in the table below,
as it relates to deferred stock units granted to directors in lieu of cash compensation.
Share-based compensation expense has been included in our condensed consolidated statements of
operations for the three months ended March 31, 2009 and 2008 as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended |
|
|
|
March 31, |
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
Cost of revenue |
|
$ |
218 |
|
|
$ |
186 |
|
Sales and marketing |
|
|
353 |
|
|
|
423 |
|
General and administrative |
|
|
1,848 |
|
|
|
1,655 |
|
Research and development |
|
|
443 |
|
|
|
547 |
|
|
|
|
|
|
|
|
Total |
|
$ |
2,862 |
|
|
$ |
2,811 |
|
|
|
|
|
|
|
|
The fair value of options, restricted stock units, deferred stock units with vesting
conditions, and employee stock purchase rights awarded during the three months ended March 31, 2009
and 2008 totaled $15.1 million and $17.9 million, respectively. The total unrecognized compensation cost
for unvested share-based compensation awards outstanding at March 31, 2009, before consideration of
estimated forfeitures, was $42.8 million. We estimate that this cost will be reduced by
approximately $3.9 million related to forfeitures. The weighted average remaining expense
recognition period at March 31, 2009 was approximately 2.3 years.
7
Options
We determine the assumptions to be used in the valuation of option grants as of the date of
grant. Differences in the terms of options granted to different segments of employees may
necessitate distinct valuation assumptions for those segments. As such, we may use different
assumptions during the fiscal year if we grant options at different dates or with varying terms.
The weighted averages of the valuation assumptions used to determine the fair value of each option
grant on the date of grant and the weighted average estimated fair values were as follows:
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended |
|
|
|
March 31, |
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
Expected stock price volatility |
|
|
30 |
% |
|
|
25 |
% |
Expected term, in years |
|
|
4.8 |
|
|
|
4.9 |
|
Risk-free interest rate |
|
|
1.6 |
% |
|
|
2.7 |
% |
|
|
|
|
|
|
|
|
|
Weighted average fair value of options granted |
|
$ |
9.97 |
|
|
$ |
15.31 |
|
The total fair value of options that vested during the three months ended March 31, 2009 and
2008 was $9.5 million and $10.2 million, respectively.
Restricted and Other Deferred Stock Units with Vesting Conditions
The combined weighted average fair value per unit of restricted stock units and deferred stock
units with vesting conditions granted during the three months ended March 31, 2009 and 2008 was
$34.37 and $56.95, respectively.
NOTE 4. INVENTORIES
Inventories include material, labor and overhead, and are stated at the lower of cost
(first-in, first-out) or market. The components of inventories were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
December 31, |
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
Raw materials |
|
$ |
37,912 |
|
|
$ |
32,575 |
|
Work-in-process |
|
|
17,789 |
|
|
|
18,428 |
|
Finished goods |
|
|
67,874 |
|
|
|
64,923 |
|
|
|
|
|
|
|
|
|
|
$ |
123,575 |
|
|
$ |
115,926 |
|
|
|
|
|
|
|
|
NOTE 5. PROPERTY AND EQUIPMENT
Net property and equipment consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
December 31, |
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
Land and improvements |
|
$ |
7,127 |
|
|
$ |
8,189 |
|
Buildings and improvements |
|
|
89,936 |
|
|
|
90,042 |
|
Leasehold improvements |
|
|
17,714 |
|
|
|
17,275 |
|
Machinery and equipment |
|
|
105,110 |
|
|
|
106,632 |
|
Office furniture and equipment |
|
|
76,447 |
|
|
|
74,885 |
|
Construction in progress |
|
|
26,615 |
|
|
|
23,175 |
|
|
|
|
|
|
|
|
|
|
|
322,949 |
|
|
|
320,198 |
|
Less accumulated depreciation and amortization |
|
|
136,241 |
|
|
|
130,552 |
|
|
|
|
|
|
|
|
Total property and equipment, net |
|
$ |
186,708 |
|
|
$ |
189,646 |
|
|
|
|
|
|
|
|
Depreciation expense was $9.9 million and $8.3 million for the three months ended March 31,
2009 and 2008, respectively.
8
NOTE 6. GOODWILL AND OTHER INTANGIBLE ASSETS
Intangible assets other than goodwill consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2009 |
|
|
December 31, 2008 |
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
Accumulated |
|
|
|
Cost |
|
|
Amortization |
|
|
Cost |
|
|
Amortization |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Patents |
|
$ |
9,710 |
|
|
$ |
4,524 |
|
|
$ |
9,748 |
|
|
$ |
4,306 |
|
Product rights (1) |
|
|
31,127 |
|
|
|
13,425 |
|
|
|
32,187 |
|
|
|
13,180 |
|
Customer-related intangible assets (2) |
|
|
51,599 |
|
|
|
12,627 |
|
|
|
52,642 |
|
|
|
11,844 |
|
Other, primarily noncompete agreements |
|
|
6,131 |
|
|
|
3,401 |
|
|
|
6,268 |
|
|
|
3,188 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
98,567 |
|
|
$ |
33,977 |
|
|
$ |
100,845 |
|
|
$ |
32,518 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Product rights comprise certain technologies, licenses, trade names and contractual rights
acquired from third parties. |
|
(2) |
|
Customer-related intangible assets comprise customer lists and customer relationships
acquired from third parties. |
Amortization expense of intangible assets was $2.4 million and $2.6 million for the three
months ended March 31, 2009 and 2008, respectively.
Goodwill by segment consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
December 31, |
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
CAG segment |
|
$ |
107,723 |
|
|
$ |
109,502 |
|
Water segment |
|
|
12,596 |
|
|
|
12,757 |
|
Production animal segment |
|
|
9,308 |
|
|
|
9,978 |
|
Other segment |
|
|
6,531 |
|
|
|
6,531 |
|
|
|
|
|
|
|
|
|
|
$ |
136,158 |
|
|
$ |
138,768 |
|
|
|
|
|
|
|
|
We did not enter into any acquisition-related transactions during the three months ended March
31, 2009. The changes in the cost of intangible assets other than goodwill and the changes in
goodwill during the three months ended March 31, 2009 resulted from changes in foreign currency
exchange rates.
NOTE 7. WARRANTY RESERVES
We provide for the estimated cost of instrument warranties in cost of product revenue at the
time revenue is recognized based on the estimated cost to repair the instrument over its warranty
period. Cost of revenue reflects not only estimated warranty expense for the systems sold in the
current period, but also any changes in estimated warranty expense for the installed base that
results from our quarterly evaluation of service experience. Our actual warranty obligation is
affected by instrument performance in the customers environment and costs incurred in servicing
instruments. Should actual service rates or costs differ from our estimates, which are based on
historical data and projections of future costs, revisions to our estimated warranty liability
would be required.
Following is a summary of changes in accrued warranty reserves during the three months ended
March 31, 2009 and 2008 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended |
|
|
|
March 31, |
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
Balance, beginning of period |
|
$ |
2,837 |
|
|
$ |
1,667 |
|
Provision for warranty expense |
|
|
1,264 |
|
|
|
507 |
|
Change in estimate, balance beginning of period |
|
|
(69 |
) |
|
|
(66 |
) |
Settlement of warranty liability |
|
|
(926 |
) |
|
|
(547 |
) |
|
|
|
|
|
|
|
Balance, end of period |
|
$ |
3,106 |
|
|
$ |
1,561 |
|
|
|
|
|
|
|
|
9
NOTE 8. DEBT
At March 31, 2009 we had $165.5 million outstanding under our unsecured short-term revolving
credit facility (Credit Facility) with a weighted average interest rate of 1.1%, which
approximates the rate that we would
pay on additional borrowings with similar maturities under the Credit Facility at March 31,
2009. Of the total amount outstanding at March 31, 2009, $6.5 million was borrowed by our Canadian
subsidiary and denominated in Canadian dollars. The applicable interest rates on our Credit
Facility generally range from 0.375 to 0.875 percentage points (Credit Spread) above the London
interbank rate or the Canadian Dollar-denominated bankers acceptance rate, dependent on our
leverage ratio.
In March 2009, we entered into two forward fixed interest rate swap agreements to manage the
economic effect of variable interest obligations. See Note 16 for a discussion of our derivative
instruments and hedging activities.
NOTE 9. INCOME TAXES
Our effective income tax rates were 31.5% and 27.9% for the three months ended March 31, 2009
and 2008, respectively. The increase in the effective tax rate for the three months ended March 31,
2009 as compared to the three months ended March 31, 2008 relates primarily to a reduction in
international deferred tax liabilities in 2008 due to a change in the statutory tax rates for a
jurisdiction in which we operate. This non-recurring benefit of approximately $1.5 million reduced
our effective income tax rate for the three months ended March 31, 2008 by 3.9 percentage points.
The impact of the non-recurring item was partly offset by federal research and development tax
incentives that were available for the three months ended March 31, 2009 due to a change in the tax
law, but not available for the three months ended March 31, 2008.
NOTE 10. COMPREHENSIVE INCOME
The following is a summary of comprehensive income for the three months ended March 31, 2009
and 2008 (in thousands):
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended |
|
|
|
March 31, |
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
Net income |
|
$ |
26,071 |
|
|
$ |
27,551 |
|
Other comprehensive income (loss): |
|
|
|
|
|
|
|
|
Foreign currency translation adjustments |
|
|
(7,093 |
) |
|
|
10,021 |
|
Change in fair value of foreign currency contracts classified as hedges, net of tax |
|
|
(1,287 |
) |
|
|
(1,281 |
) |
Change in fair value of interest rate swaps classified as hedges, net of tax |
|
|
(213 |
) |
|
|
|
|
Change in fair market value of investments, net of tax |
|
|
(63 |
) |
|
|
(73 |
) |
|
|
|
|
|
|
|
Comprehensive income |
|
$ |
17,415 |
|
|
$ |
36,218 |
|
|
|
|
|
|
|
|
NOTE 11. EARNINGS PER SHARE
Basic earnings per share is computed by dividing net income by the weighted average number of
shares of common stock and vested deferred stock units outstanding during the year. The computation
of diluted earnings per share is similar to the computation of basic earnings per share, except
that the denominator is increased for the assumed exercise of dilutive options and other
potentially dilutive securities using the treasury stock method, unless the effect is
anti-dilutive.
10
The following is a reconciliation of shares outstanding for basic and diluted earnings per
share (in thousands):
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended |
|
|
|
March 31, |
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
Shares outstanding for basic earnings per share: |
|
|
|
|
|
|
|
|
Weighted average shares outstanding |
|
|
59,064 |
|
|
|
60,774 |
|
Weighted average vested deferred stock units outstanding |
|
|
108 |
|
|
|
91 |
|
|
|
|
|
|
|
|
|
|
|
59,172 |
|
|
|
60,865 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares outstanding for diluted earnings per share: |
|
|
|
|
|
|
|
|
Shares outstanding for basic earnings per share |
|
|
59,172 |
|
|
|
60,865 |
|
Dilutive effect of options issued to employees and directors |
|
|
1,386 |
|
|
|
2,590 |
|
Dilutive effect of restricted stock units issued to employees and
directors |
|
|
41 |
|
|
|
95 |
|
Dilutive effect of unvested deferred stock units issued to directors |
|
|
7 |
|
|
|
8 |
|
|
|
|
|
|
|
|
|
|
|
60,606 |
|
|
|
63,558 |
|
|
|
|
|
|
|
|
Vested deferred stock units outstanding are included in shares outstanding for basic and
diluted earnings per share because the associated shares of our common stock are issuable for no
cash consideration, the number of shares of our common stock to be issued is fixed, and issuance is
not contingent.
Certain options to acquire shares and restricted stock units have been excluded from the
calculation of shares outstanding for dilutive earnings per share because they were anti-dilutive.
The following table presents information concerning those anti-dilutive options and restricted
stock units (in thousands, except per share amounts):
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended |
|
|
|
March 31, |
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares underlying anti-dilutive options |
|
|
1,432 |
|
|
|
451 |
|
|
|
|
|
|
|
|
|
|
Weighted average exercise price per underlying share of anti-dilutive options |
|
$ |
44.60 |
|
|
$ |
52.62 |
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares underlying anti-dilutive restricted stock units |
|
|
302 |
|
|
|
92 |
|
The following table presents additional information concerning the exercise prices of vested
and unvested options outstanding at the end of the period (in thousands, except per share amounts):
|
|
|
|
|
|
|
|
|
|
|
March 31, |
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
Closing price per share of our common stock |
|
$ |
34.58 |
|
|
$ |
49.26 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares underlying options with exercise prices below the closing price |
|
|
4,382 |
|
|
|
4,999 |
|
Number of shares underlying options with exercise prices equal to or above the closing price |
|
|
1,104 |
|
|
|
611 |
|
|
|
|
|
|
|
|
Total number of shares underlying outstanding options |
|
|
5,486 |
|
|
|
5,610 |
|
|
|
|
|
|
|
|
NOTE 12. COMMITMENTS, CONTINGENCIES AND GUARANTEES
Significant commitments, contingencies and guarantees at March 31, 2009 are consistent with
those discussed in our Annual Report on Form 10-K for the year ended December 31, 2008 in Note 12
to the consolidated financial statements.
11
NOTE 13. TREASURY STOCK
Our board of directors has authorized the repurchase of up to 40,000,000 shares of our common
stock in the open market or in negotiated transactions. We believe that the repurchase of our
common stock is a favorable investment and we also repurchase to offset the dilutive effect of our
share-based compensation programs.
Repurchases of our common stock may vary depending upon the level of other investing and
financing activities and the share price.
From the inception of the program in August 1999 to March 31, 2009, we repurchased 36,255,000
shares for $837.5 million. From the inception of the program to March 31, 2009, we also received
408,000 shares of stock with a market value of $8.9 million that were surrendered by employees in
payment for the minimum required withholding taxes due on the exercise of stock options, the
vesting of restricted stock units and the settlement of deferred stock units, and in payment for
the exercise price of stock options.
Information about our treasury stock purchases and other receipts is presented in the table
below (in thousands, except per share amounts):
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended |
|
|
|
March 31, |
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
Shares acquired |
|
|
499 |
|
|
|
973 |
|
Total cost of shares acquired |
|
$ |
16,058 |
|
|
$ |
52,650 |
|
Average cost per share |
|
$ |
32.20 |
|
|
$ |
54.10 |
|
NOTE 14. SEGMENT REPORTING
We are organized into business units by market and customer group. Our reportable segments
include: products and services for the veterinary market, which we refer to as our Companion Animal
Group (CAG), water quality products (Water), and products for production animal health, which
we refer to as our Production Animal Segment (PAS). We also operate two smaller segments that
comprise products for dairy quality, which we refer to as Dairy, and products for the human medical
diagnostic market, which we refer to as OPTI Medical. In addition, we maintain active research and
development programs, some of which may materialize into the development and introduction of new
technology, products or services. Financial information about our Dairy and OPTI Medical operating
segments and other activities are combined and presented in an Other category because they do not
meet the quantitative or qualitative thresholds for reportable segments.
CAG develops, designs, manufactures, and distributes products and performs services for
veterinarians. Water develops, designs, manufactures, and distributes products to detect
contaminants in water. PAS develops, designs, manufactures, and distributes products to detect
disease in production animals. Dairy develops, designs, manufactures, and distributes products to
detect contaminants in dairy products. OPTI Medical develops, designs, manufactures, and
distributes point-of-care electrolyte and blood gas analyzers and related consumable products for
the human medical diagnostics market. In connection with the restructuring of our pharmaceutical
business at the end of 2008, we realigned two of our remaining pharmaceutical product lines to
Rapid Assay products within our CAG segment, and realigned the remainder of our pharmaceutical
business, which comprised one product line and two out-licensing arrangements, to the Other
category. The segment information for the three months ended March 31, 2008 has been restated to
conform to our presentation of reportable segments for the three months ended March 31, 2009.
Previously, financial information related to the product lines realigned to Rapid Assay and the
product line and out-licensing arrangement realigned to Other were included in the pharmaceutical
business and reported in our CAG segment.
Items that are not allocated to our operating segments are comprised primarily of corporate
research and development expenses that do not align with one of our existing business or service
categories, a portion of share-based compensation expense, interest income and expense, and income
taxes. We allocate most of our share-based compensation expense to the operating segments. This
allocation differs from the actual expense and consequently yields a difference between the total
allocated share-based compensation expense and the actual expense for the total company, which is
categorized as unallocated amounts.
The accounting policies of the segments are the same as those described in the summary of
significant accounting policies in our Annual Report on Form 10-K for the year ended December 31,
2008 in Notes 3 and 17.
12
The following is the segment information (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended March 31, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unallocated |
|
|
Consolidated |
|
|
|
CAG |
|
|
Water |
|
|
PAS |
|
|
Other |
|
|
Amounts |
|
|
Total |
|
2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues |
|
$ |
193,692 |
|
|
$ |
15,851 |
|
|
$ |
18,266 |
|
|
$ |
8,646 |
|
|
$ |
|
|
|
$ |
236,455 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from operations |
|
$ |
29,079 |
|
|
$ |
7,312 |
|
|
$ |
4,950 |
|
|
$ |
129 |
|
|
$ |
(3,029 |
) |
|
$ |
38,441 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense, net |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
396 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before provision for income
taxes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
38,045 |
|
Provision for income taxes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11,974 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
26,071 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues |
|
$ |
202,791 |
|
|
$ |
16,816 |
|
|
$ |
21,162 |
|
|
$ |
8,305 |
|
|
$ |
|
|
|
$ |
249,074 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from operations |
|
$ |
29,124 |
|
|
$ |
6,270 |
|
|
$ |
5,828 |
|
|
$ |
242 |
|
|
$ |
(2,745 |
) |
|
$ |
38,719 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense, net |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
485 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before provision for income
taxes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
38,234 |
|
Provision for income taxes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10,683 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
27,551 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue by product and service category was as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended |
|
|
|
March 31, |
|
|
|
2009 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
CAG segment revenue: |
|
|
|
|
|
|
|
|
Instruments and consumables |
|
$ |
72,235 |
|
|
$ |
75,610 |
|
Rapid assay products |
|
|
37,677 |
|
|
|
38,711 |
|
Laboratory and consulting services |
|
|
68,692 |
|
|
|
70,107 |
|
Practice information systems and digital radiography |
|
|
15,034 |
|
|
|
15,025 |
|
Pharmaceutical products |
|
|
54 |
|
|
|
3,338 |
|
|
|
|
|
|
|
|
CAG segment revenue |
|
|
193,692 |
|
|
|
202,791 |
|
|
|
|
|
|
|
|
|
|
Water segment revenue |
|
|
15,851 |
|
|
|
16,816 |
|
PAS segment revenue |
|
|
18,266 |
|
|
|
21,162 |
|
Other segment revenue |
|
|
8,646 |
|
|
|
8,305 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue |
|
$ |
236,455 |
|
|
$ |
249,074 |
|
|
|
|
|
|
|
|
NOTE 15. FAIR VALUE MEASUREMENTS
On January 1, 2008, we adopted the provisions of SFAS No. 157 for our financial assets and
liabilities. We adopted the provisions of SFAS No. 157 for nonfinancial assets and nonfinancial
liabilities, which were previously deferred by FSP No. SFAS 157-2, on January 1, 2009. SFAS No. 157
provides a framework for measuring fair value under U.S. GAAP and requires expanded disclosures
regarding fair value measurements. SFAS No. 157 defines fair value as the exchange price that would
be received for an asset or paid to transfer a liability (an exit price) in the principal or most
advantageous market for the asset or liability in an orderly transaction between market
participants on the measurement date. SFAS No. 157 also establishes a fair value hierarchy which
requires an entity to maximize the use of observable inputs, where available, and minimize the use
of unobservable inputs when measuring fair value.
13
SFAS No. 157 describes three levels of inputs that may be used to measure fair value:
|
|
|
Level 1
|
|
Quoted prices in active markets for identical assets or
liabilities. Our Level 1 assets and liabilities include
investments in money market funds and marketable securities
related to a deferred compensation plan assumed in a business
combination. The liabilities associated with this plan relate to
deferred compensation, which is indexed to the performance of the
underlying investments. |
|
|
|
Level 2
|
|
Observable inputs other than Level 1 prices, such as quoted prices
for similar assets or liabilities; quoted prices in markets that
are not active; or other inputs that are observable or can be
corroborated by observable market data for substantially the full
term of the assets or liabilities. Our Level 2 assets include
unrealized gains and losses on foreign currency and interest rate
hedge contracts, respectively. |
|
|
|
Level 3
|
|
Unobservable inputs that are supported by little or no market
activity and that are significant to the fair value of the assets
or liabilities. At March 31, 2009, we had no Level 3 assets or
liabilities. |
The following tables set forth our financial assets and liabilities that were measured at fair
value on a recurring basis at March 31, 2009 and December 31, 2008 by level within the fair value
hierarchy. We did not have any nonfinancial assets or nonfinancial liabilities falling under the
scope of FSP No. SFAS 157-2 which required remeasurement during the three months ended March 31,
2009. As required by SFAS No. 157, assets and liabilities measured at fair value are classified in
their entirety based on the lowest level of input that is significant to the fair value
measurement. Our assessment of the significance of a particular input to the fair value measurement
in its entirety requires judgment and considers factors specific to the asset or liability (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quoted Prices |
|
|
Significant |
|
|
|
|
|
|
|
|
|
in Active |
|
|
Other |
|
|
Significant |
|
|
|
|
|
|
Markets for |
|
|
Observable |
|
|
Unobservable |
|
|
|
|
|
|
Identical Assets |
|
|
Inputs |
|
|
Inputs |
|
|
Balance at |
|
|
|
(Level 1) |
|
|
(Level 2) |
|
|
(Level 3) |
|
|
March 31, 2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Marketable securities (1) |
|
$ |
1,294 |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
1,294 |
|
Money market funds (2) |
|
|
2,004 |
|
|
|
|
|
|
|
|
|
|
|
2,004 |
|
Foreign currency exchange contracts (3) |
|
|
|
|
|
|
8,067 |
|
|
|
|
|
|
|
8,067 |
|
Liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred compensation (4) |
|
|
1,294 |
|
|
|
|
|
|
|
|
|
|
|
1,294 |
|
Interest rate swaps (5) |
|
|
|
|
|
|
338 |
|
|
|
|
|
|
|
338 |
|
|
|
|
(1) |
|
Investments in marketable securities for a deferred compensation plan, which is included in
other long-term assets. |
|
(2) |
|
Short-term investment in registered funds and included in cash and cash equivalents. |
|
(3) |
|
Unrealized gains on hedge contracts, included in other current assets. The notional value of these
contracts is $118.1 million. |
|
(4) |
|
Deferred compensation liability associated with the above-mentioned marketable securities,
included in other long-term liabilities. |
|
(5) |
|
Unrealized losses on fixed interest rate swaps designated as cash flow hedges, included in
accrued expenses whereby we will receive variable interest rate payments in exchange for fixed
interest payments on $80 million of borrowings outstanding beginning on March 31, 2010,
extending through March 30, 2012. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quoted Prices |
|
|
Significant |
|
|
|
|
|
|
|
|
|
in Active |
|
|
Other |
|
|
Significant |
|
|
|
|
|
|
Markets for |
|
|
Observable |
|
|
Unobservable |
|
|
|
|
|
|
Identical Assets |
|
|
Inputs |
|
|
Inputs |
|
|
Balance at |
|
|
|
(Level 1) |
|
|
(Level 2) |
|
|
(Level 3) |
|
|
December 31, 2008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Marketable securities (1) |
|
$ |
1,384 |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
1,384 |
|
Money market funds (2) |
|
|
9,017 |
|
|
|
|
|
|
|
|
|
|
|
9,017 |
|
Foreign currency exchange contracts (3) |
|
|
|
|
|
|
9,932 |
|
|
|
|
|
|
|
9,932 |
|
Liabilities |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred compensation (4) |
|
|
1,384 |
|
|
|
|
|
|
|
|
|
|
|
1,384 |
|
|
|
|
(1) |
|
Investments in marketable securities for a deferred compensation plan, which is included in
other long-term assets. |
|
(2) |
|
Short-term investment in registered funds and included in cash and cash equivalents. |
|
(3) |
|
Unrealized gains on hedge contracts, included in other current assets. The notional value of these
contracts is $97.7 million. |
|
(4) |
|
Deferred compensation liability associated with the above-mentioned marketable securities,
included in other long-term liabilities. |
14
NOTE 16. DERIVATIVE INSTRUMENTS AND HEDGING
On January 1, 2009, we adopted the provisions of SFAS No. 161, which requires entities to
provide greater transparency in interim and annual financial statements about how and why the
entity uses derivative instruments, how the instruments and related hedged items are accounted for
under SFAS No. 133, and how the instruments and related hedged items affect the financial position,
results of operations, and cash flows of the entity.
We are exposed to certain risks related to our ongoing business operations. The primary risks
that we manage by using derivative instruments are foreign currency exchange risk and interest rate
risk. Our subsidiaries enter into foreign currency exchange contracts to manage the exchange risk
associated with their forecasted intercompany inventory purchases for the next year. From time to
time, we may also enter into foreign currency exchange contracts to minimize the impact of foreign
currency fluctuations associated with specific, significant transactions. Interest rate swaps are
entered into to manage interest rate risk associated with our variable-rate debt.
SFAS No. 133 requires that derivative instruments be recognized on the balance sheet as either
assets or liabilities at fair value. We have designated our forward currency exchange contracts and
variable-to-fixed interest rate swaps as cash flow hedges.
Cash Flow Hedges
For derivative instruments that are designated as hedges, changes in the fair value of the
derivative are recognized in other comprehensive income and reclassified into earnings in the same
period or periods during which the hedged transaction affects earnings. We de-designate derivative
instruments from hedge accounting when the probability of the hedged transaction occurring becomes
less than probable, but remains reasonably possible. For de-designated instruments, the gain or
loss from the time of de-designation through maturity of the instrument is recognized in earnings.
Any gain or loss in other comprehensive income at the time of de-designation is reclassified into
earnings in the same period or periods during which the hedged transaction affects earnings. There
was no gain or loss recognized in earnings related to de-designated instruments during the three
months ended March 31, 2009 or 2008. We immediately record in earnings the extent to which a hedge
is not effective in achieving offsetting changes in fair value of the hedged item. There was no
gain or loss recognized in earnings related to hedge ineffectiveness during the three months ended
March 31, 2009 or 2008. At March 31, 2009 the estimated net amount of gains that are expected to be
reclassified out of accumulated other comprehensive income and into earnings within the next 12
months is $7.9 million.
We enter into currency exchange contracts for amounts that are less than the full value of
forecasted intercompany sales. Our hedging strategy related to intercompany inventory purchases
provides that we employ the full amount of our hedges for the succeeding year at the conclusion of
our budgeting process for that year, which is complete by the end of the preceding year. Quarterly,
we enter into contracts to hedge incremental portions of anticipated foreign currency transactions
for the following year. Accordingly, our risk with respect to foreign currency exchange rate
fluctuations may vary throughout each annual cycle.
The primary purpose of our foreign currency hedging activities is to protect against the
volatility associated with foreign currency transactions. We also utilize natural hedges to
mitigate our transaction and commitment exposures. Our corporate policy prescribes the range of
allowable hedging activity. We enter into exchange contracts with large multinational financial
institutions and we do not hold or engage in transactions involving derivative instruments for
purposes other than risk management. Our accounting policies for these contracts are based on our
designation of such instruments as hedging transactions. Market gains and losses are deferred in
other current or long-term assets or accruals, as appropriate, until the contract matures, which is the period
when the related obligation is settled. We primarily utilize forward exchange contracts with
durations of less than 21 months.
In March 2009, we entered into two forward fixed interest rate swap agreements to manage the
economic effect of variable interest obligations on amounts borrowed under the terms of our Credit
Facility. Under these agreements, the variable interest rate associated with $80 million of
borrowings outstanding beginning on March 31, 2010 will effectively become fixed at 2% plus the
Credit Spread through March 30, 2012. The critical terms of the interest rate swap agreements match
the critical terms of the underlying borrowings, including notional amounts, underlying market
indices, interest rate reset dates and maturity dates.
15
The notional amount of foreign currency contracts to hedge forecasted intercompany sales
consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Dollar Equivalent |
|
|
|
March 31, |
|
|
December 31, |
|
|
March 31, |
|
Currency Sold |
|
2009 |
|
|
2008 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Euro |
|
$ |
48,843 |
|
|
$ |
44,907 |
|
|
$ |
51,132 |
|
British Pound |
|
|
23,541 |
|
|
|
20,540 |
|
|
|
20,804 |
|
Canadian Dollar |
|
|
24,740 |
|
|
|
16,960 |
|
|
|
14,420 |
|
Australian Dollar |
|
|
6,414 |
|
|
|
3,641 |
|
|
|
5,350 |
|
Swiss Franc |
|
|
|
|
|
|
|
|
|
|
854 |
|
Japanese Yen |
|
|
7,253 |
|
|
|
6,318 |
|
|
|
4,755 |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
110,791 |
|
|
$ |
92,366 |
|
|
$ |
97,315 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Dollar Equivalent |
|
|
|
March 31, |
|
|
December 31, |
|
|
March 31, |
|
Currency Purchased |
|
2009 |
|
|
2008 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Swiss Franc |
|
$ |
7,306 |
|
|
$ |
5,383 |
|
|
$ |
5,279 |
|
Japanese Yen |
|
|
|
|
|
|
|
|
|
|
221 |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ |
7,306 |
|
|
$ |
5,383 |
|
|
$ |
5,500 |
|
|
|
|
|
|
|
|
|
|
|
The notional amount of forward fixed interest rate swap agreements to manage variable interest
obligations consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. Dollar Equivalent |
|
|
|
March 31, |
|
|
December 31, |
|
|
March 31, |
|
|
|
2009 |
|
|
2008 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate swap |
|
$ |
80,000 |
|
|
$ |
|
|
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
The fair values of derivative instruments and their respective classification in the condensed
consolidated balance sheet consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Asset Derivatives |
|
|
|
March 31, 2009 |
|
|
December 31, 2008 |
|
|
|
Balance Sheet |
|
|
|
|
|
|
Balance Sheet |
|
|
|
|
|
|
Classification |
|
|
Fair Value |
|
|
Classification |
|
|
Fair Value |
|
Derivatives designated as
hedging instruments under
SFAS No. 133 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts |
|
Other current assets |
|
$ |
8,022 |
|
|
Other current assets |
|
$ |
9,932 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivatives not designated
as hedging instruments
under SFAS No. 133 (1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts |
|
Other current assets |
|
|
45 |
|
|
Other current assets |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total derivative instruments |
|
|
|
|
|
$ |
8,067 |
|
|
|
|
|
|
$ |
9,932 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liability Derivatives |
|
|
|
March 31, 2009 |
|
|
December 31, 2008 |
|
|
|
Balance Sheet |
|
|
|
|
|
|
Balance Sheet |
|
|
|
|
|
|
Classification |
|
|
Fair Value |
|
|
Classification |
|
|
Fair Value |
|
Derivatives
designated as
hedging instruments
under SFAS No. 133 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate swaps |
|
Accrued expenses |
|
$ |
338 |
|
|
Accrued expenses |
|
$ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Derivatives not designated as hedge instruments relate to foreign exchange contracts,
originally entered into to hedge against the volatility associated with foreign currency
transactions, where the probability of the hedged transaction occurring within the original
specified period of time changed from probable to reasonably possible. |
16
The effect of derivative instruments designated as cash flow hedges in accordance with SFAS
No. 133 on the condensed consolidated statement of operations for the three months ended March 31,
2009 and 2008 consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Classification of Gain (Loss) |
|
|
Gain (Loss) Reclassified from Accumulated |
|
|
|
Reclassified from OCI into |
|
|
OCI into Income (Effective Portion) |
|
Derivative instruments |
|
Income (Effective Portion) |
|
|
March 31, 2009 |
|
|
March 31, 2008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts |
|
Cost of revenue |
|
$ |
4,818 |
|
|
$ |
(1,755 |
) |
|
|
|
|
|
|
|
|
|
|
|
The effect of derivative instruments designated as cash flow hedges in accordance with SFAS
No. 133 on the condensed consolidated balance sheet for the three months ended March 31, 2009 and
2008 consisted of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Gain (Loss) Recognized in OCI on Derivative |
|
|
|
Instruments (Effective Portion) |
|
Derivative instruments |
|
March 31, 2009 |
|
|
March 31, 2008 |
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts, net of tax |
|
$ |
(1,287 |
) |
|
$ |
(1,281 |
) |
Interest rate swaps, net of tax |
|
|
(213 |
) |
|
|
|
|
|
|
|
|
|
|
|
Total loss, net of tax |
|
|
(1,500 |
) |
|
|
(1,281 |
) |
|
|
|
|
|
|
|
17
Item 2. Managements Discussion and Analysis of Financial Condition and Results of Operations.
This Quarterly Report on Form 10-Q contains statements which, to the extent they are not
statements of historical or present fact, constitute forward-looking statements. Such
forward-looking statements about our business and expectations within the meaning of the Private
Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended, include statements relating to
future revenue growth rates, earnings and other measures of financial performance, the effect of
economic downturns on our business performance, demand for our products, realizability of assets,
future cash flow and uses of cash, future repurchases of common stock, future levels of
indebtedness and capital spending, warranty expense, share-based compensation expense, and
competition. Forward-looking statements can be identified by the use of words such as expects,
may, anticipates, intends, would, will, plans, believes, estimates, should, and
similar words and expressions. These forward-looking statements are intended to provide our current
expectations or forecasts of future events; are based on current estimates, projections, beliefs,
and assumptions; and are not guarantees of future performance. Actual events or results may differ
materially from those described in the forward-looking statements. These forward-looking statements
involve a number of risks and uncertainties as more fully described under the heading Part II,
Item 1A. Risk Factors in this Quarterly Report on Form 10-Q. The risks and uncertainties discussed
herein do not reflect the potential impact of any mergers, acquisitions or dispositions. In
addition, any forward-looking statements represent our estimates only as of the day this Quarterly
Report was first filed with the Securities and Exchange Commission and should not be relied upon as
representing our estimates as of any subsequent date. From time to time, oral or written
forward-looking statements may also be included in other materials released to the public. While we
may elect to update forward-looking statements at some point in the future, we specifically
disclaim any obligation to do so, even if our estimates or expectations change.
Business Overview
We operate primarily through three business segments: products and services for the veterinary
market, which we refer to as our Companion Animal Group (CAG), water quality products (Water)
and products for production animal health, which we refer to as our Production Animal Segment
(PAS). We also operate two smaller segments that comprise products for dairy quality, which we
refer to as Dairy, and products for the human medical diagnostic market, which we refer to as OPTI
Medical. In addition, we maintain active
research and development programs, some of which may materialize into the development and
introduction of new technology, products or services. Financial information about our Dairy and OPTI Medical operating segments and other
activities are combined and presented in an Other category because they do not meet the
quantitative or qualitative thresholds for reportable segments. In connection with the restructuring of our
pharmaceutical business at the end of 2008, we realigned two of our remaining pharmaceutical
product lines to the Rapid Assay business, which is part of our CAG segment, and realigned the
remainder of our pharmaceutical business, which comprised one product line and two out-licensing
arrangements, to the Other category. Segment information presented for the three months ended March
31, 2008 has been restated to conform to our presentation of reportable segments for the three
months ended March 31, 2009. See Note 14 to the condensed consolidated financial statements
included in this Quarterly Report on Form 10-Q for financial information about our segments.
CAG develops, designs, manufactures, and distributes products and performs services for
veterinarians. Water develops, designs, manufactures, and distributes products to detect
contaminants in water. PAS develops, designs, manufactures, and distributes products to detect
diseases in production animals. Dairy develops, designs, manufactures, and distributes products to
detect contaminants in dairy products. OPTI Medical develops, designs, manufactures, and
distributes point-of-care electrolyte and blood gas analyzers and related consumable products for
the human medical diagnostics market.
Items that are not allocated to our operating segments are comprised primarily of corporate
research and development expenses that do not align with one of our existing business or service
categories, a portion of share-based compensation expense, interest income and expense, and income
taxes. We allocate most of our share-based compensation expense to the operating segments. This
allocation differs from the actual expense and consequently yields a difference between the total
allocated share-based compensation expense and the actual expense for the total company. In our
segment disclosure of gross profit, operating expenses and operating income, these amounts are
shown under the caption unallocated amounts.
18
Because our instrument consumables and rapid assay products are sold in the U.S. and certain
other geographies by distributors, distributor purchasing dynamics have an impact on our reported
sales of these products.
Distributors purchase products from us and sell them to veterinary practices, who are the end
users. Distributor purchasing dynamics may be affected by many factors and may be unrelated to
underlying end-user demand for our products. As a result, fluctuations in distributors inventories
may cause reported results in a period not to be representative of underlying end-user demand.
Therefore, we believe it is important to track distributor sales to end users and to distinguish
between the impact of end-user demand and the impact of distributor purchasing dynamics on reported
revenue growth.
Where growth rates are affected by changes in end-user demand, we refer to the impact of
practice-level sales on growth. Where growth rates are affected by distributor purchasing dynamics,
we refer to the impact of changes in distributors inventories. If during the comparable period of
the prior year, distributors inventories grew by more than those inventories grew in the current
year, then changes in distributors inventories have a negative impact on our reported sales growth
in the current period. Conversely, if during the comparable period of the prior year, distributors
inventories grew by less than those inventories grew in the current year, then changes in
distributors inventories have a positive impact on our reported sales growth in the current
period.
Approximately 23% of our revenue is derived from products manufactured in the U.S. and sold
internationally. Strengthening of the U.S. dollar relative to other currencies has a negative
impact on our international revenues and on margins of products manufactured in the U.S. and sold
internationally. In addition, to the extent that the U.S. dollar is stronger in future periods
relative to the exchange rates in effect in the corresponding prior periods, our growth rate will
be negatively affected. The related impact on foreign currency denominated operating expenses and
the impact of foreign currency hedge contracts in place partly offset this exposure. See also the
section of this Quarterly Report on Form 10-Q captioned Quantitative and Qualitative Disclosures
About Market Risk.
We believe that our financial results in the first quarter of 2009 continued to be negatively
impacted by economic conditions that weakened over the course of 2008 due, in large part, to fewer
patient visits to U.S. and European veterinary clinics for routine screening, preventative care and
elective procedures. In the first quarter, we also began to see impacts to capital sales reflecting
more cautious spending by veterinarians. These observations are consistent with other market data
that is available to us, particularly with respect to changes in patient visits to U.S. veterinary
medical hospitals. Beyond our companion animal business, we are also seeing economic impacts to
non-regulatory Water testing volumes, driven by a decline in new home construction and reduced
consumer willingness to spend on certain luxury items, such as vacation cruises.
While we expect these trends to continue in the near-term, we believe the fundamental drivers
of demand in our served markets remain intact and that we will be well positioned to return to more
historic growth rates when economies stabilize.
Critical Accounting Policies and Estimates
The discussion and analysis of our financial condition and results of operations is based upon
our condensed consolidated financial statements, which have been prepared in accordance with
accounting principles generally accepted in the U.S. The preparation of these financial statements
requires us to make estimates and judgments that affect the reported amounts of assets,
liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On
an ongoing basis, we evaluate our estimates. We base our estimates on historical experience and on
various other assumptions that we believe to be reasonable under the circumstances, the results of
which form the basis for making judgments about the carrying values of assets and liabilities that
are not readily apparent from other sources. Actual results may differ from these estimates. The
significant accounting policies used in preparation of these condensed consolidated financial
statements for the three months ended March 31, 2009 are consistent with those discussed in Note 3
to the consolidated financial statements included in our Annual Report on Form 10-K for the year
ended December 31, 2008. The critical accounting policies and the significant judgments and
estimates used in the preparation of our condensed consolidated financial statements for the three
months ended March 31, 2009 are consistent with those discussed in our Annual Report on Form 10-K
for the year ended December 31, 2008 in the section captioned Managements Discussion and Analysis
of Financial Condition and Results of OperationsCritical Accounting Policies and Estimates.
19
Results of Operations
Three Months Ended March 31, 2009 Compared to Three Months Ended March 31, 2008
Revenue
Total Company. The following table presents revenue by operating segment:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended March 31, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change Net of |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage |
|
|
Acquisitions/ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage |
|
|
Change from |
|
|
Divestitures |
|
Net Revenue |
|
|
|
|
|
|
|
|
|
Dollar |
|
|
Percentage |
|
|
Change from |
|
|
Acquisitions/ |
|
|
and Currency |
|
(dollars in thousands) |
|
2009 |
|
|
2008 |
|
|
Change |
|
|
Change |
|
|
Currency (1) |
|
|
Divestitures (2) |
|
|
Effect |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CAG |
|
$ |
193,692 |
|
|
$ |
202,791 |
|
|
$ |
(9,099 |
) |
|
|
(4.5 |
%) |
|
|
(6.0 |
%) |
|
|
(1.6 |
%) |
|
|
3.1 |
% |
Water |
|
|
15,851 |
|
|
|
16,816 |
|
|
|
(965 |
) |
|
|
(5.7 |
%) |
|
|
(8.3 |
%) |
|
|
|
|
|
|
2.6 |
% |
PAS |
|
|
18,266 |
|
|
|
21,162 |
|
|
|
(2,896 |
) |
|
|
(13.7 |
%) |
|
|
(9.7 |
%) |
|
|
|
|
|
|
(4.0 |
%) |
Other |
|
|
8,646 |
|
|
|
8,305 |
|
|
|
341 |
|
|
|
4.1 |
% |
|
|
(1.8 |
%) |
|
|
|
|
|
|
5.9 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
236,455 |
|
|
$ |
249,074 |
|
|
$ |
(12,619 |
) |
|
|
(5.1 |
%) |
|
|
(6.4 |
%) |
|
|
(1.3 |
%) |
|
|
2.6 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Represents the percentage change in revenue attributed to the effect of changes in currency
rates from the three months ended March 31, 2008 to the three months ended March 31, 2009. |
|
(2) |
|
Represents the percentage change in revenue during the three months ended March 31, 2009
compared to the three months ended March 31, 2008 attributed to incremental revenues from
businesses acquired or revenues lost from businesses divested subsequent to December 31, 2007. |
Companion Animal Group. The following table presents revenue by product and service category
for CAG:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended March 31, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Change Net of |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage |
|
|
Acquisitions/ |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Percentage |
|
|
Change from |
|
|
Divestitures |
|
Net Revenue |
|
|
|
|
|
|
|
|
|
Dollar |
|
|
Percentage |
|
|
Change from |
|
|
Acquisitions/ |
|
|
and Currency |
|
(dollars in thousands) |
|
2009 |
|
|
2008 |
|
|
Change |
|
|
Change |
|
|
Currency (1) |
|
|
Divestitures (2) |
|
|
Effect |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Instruments and
consumables |
|
$ |
72,235 |
|
|
$ |
75,610 |
|
|
$ |
(3,375 |
) |
|
|
(4.5 |
%) |
|
|
(7.3 |
%) |
|
|
|
|
|
|
2.8 |
% |
Rapid assay products |
|
|
37,677 |
|
|
|
38,711 |
|
|
|
(1,034 |
) |
|
|
(2.7 |
%) |
|
|
(1.7 |
%) |
|
|
|
|
|
|
(1.0 |
%) |
Laboratory and consulting
services |
|
|
68,692 |
|
|
|
70,107 |
|
|
|
(1,415 |
) |
|
|
(2.0 |
%) |
|
|
(7.8 |
%) |
|
|
|
|
|
|
5.8 |
% |
Practice information
management systems
and digital radiography |
|
|
15,034 |
|
|
|
15,025 |
|
|
|
9 |
|
|
|
0.1 |
% |
|
|
(3.0 |
%) |
|
|
|
|
|
|
3.1 |
% |
Pharmaceutical products |
|
|
54 |
|
|
|
3,338 |
|
|
|
(3,284 |
) |
|
|
(98.4 |
%) |
|
|
|
|
|
|
(100.0 |
%) |
|
|
1.6 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net CAG revenue |
|
$ |
193,692 |
|
|
$ |
202,791 |
|
|
$ |
(9,099 |
) |
|
|
(4.5 |
%) |
|
|
(6.0 |
%) |
|
|
(1.6 |
%) |
|
|
3.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Represents the percentage change in revenue attributed to the effect of changes in currency
rates from the three months ended March 31, 2008 to the three months ended March 31, 2009. |
|
(2) |
|
Represents the percentage change in revenue during the three months ended March 31, 2009
compared to the three months ended March 31, 2008 attributed to incremental revenues from
businesses acquired or revenues lost from businesses divested subsequent to December 31, 2007. |
The following revenue analysis reflects the results of operations net of the impact of
currency exchange rates on sales outside the U.S. and net of incremental sales from businesses
acquired or revenues lost from businesses divested subsequent to December 31, 2007.
Instruments and consumables revenue increased due to higher instrument sales volumes and
higher average unit sales prices realized on most of our consumable products, primarily on slides
that are sold for use in our chemistry analyzers, partly offset by lower consumables sales volume.
Higher instrument sales volumes were driven by sales of Catalyst Dx chemistry analyzers and
SNAPshot Dx® analyzers, which were both launched at the end of the first quarter of
2008. The increase in volume due to the placements of these instruments was partly offset by a
decrease in sales of most of our other IDEXX VetLab® instruments, due primarily to
a shift in focus of our sales team to our newer instruments. The decrease in the volume of
consumables was due primarily to reductions in distributor inventories, partly offset by higher
volume of sales of consumables used with our newer instruments. Higher instrument service revenue
was due to the increase in number of instruments covered under service contracts as our active
installed base of instruments continued to increase. The impact from changes in distributors
inventory levels reduced reported instruments and consumables revenue growth by 3%.
20
The decrease in rapid assay sales was due to changes in distributor inventories, partially
offset by higher practice-level sales. The increase in practice-level sales was due primarily to
higher sales volumes of canine combination test products, resulting from customer purchase programs
offering promotional discounting on purchases made in the first quarter. The favorable impact that
the promotional programs had on sales volume was partly offset by the unfavorable impact of the
programs on average unit sales prices. The impact from changes in distributors inventory levels
reduced reported rapid assay revenue growth by 5%.
The increase in sales of laboratory and consulting services was primarily driven by the impact
of price increases.
The increase in sales of practice information management systems and digital radiography
resulted primarily from higher sales volumes of companion animal radiography systems and, to a
lesser extent, increased sales of hardware and peripheral equipment used with practice information
management systems. These favorable impacts were partly offset by lower sales volumes of equine
digital radiography systems and lower average unit prices for companion animal radiography systems.
Pharmaceutical revenue was not significant in the first quarter of 2009. In the fourth quarter
of 2008, we sold a substantial portion of our pharmaceutical assets and product lines, and
therefore will not have recurring pharmaceutical product revenue beyond the first quarter of 2009.
We have retained certain intellectual property and licenses for developed products as well as
certain less significant product lines, which have been reassigned to other business units.
Water. The decrease in Water revenue resulted primarily from the unfavorable impact of
currency exchange rates and lower sales volume of our Colilert® product, partly offset
by higher average unit sales prices. Higher average unit sales prices were attributable to higher
relative sales in geographies where products are sold at higher average unit sales prices, and to
the impact of first-quarter price increases for certain products sold in the U.S. and other
regions. The unfavorable impact of currency exchange rates reduced reported Water revenue by 8%.
Production Animal Segment. The decrease in PAS revenue resulted primarily from the unfavorable
impact of currency exchange rates, which reduced reported PAS revenue by 10%, and from lower
average unit sales prices for certain bovine tests, partly offset by higher average unit sales
prices for our poultry tests.
Other. The increase in Other operating units revenue was due primarily to higher sales volume
of OPTI Medical products and of Dairy SNAP® antibiotic residue tests.
Gross Profit
Total Company. The following table presents gross profit and gross profit percentages by
operating segment:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended March 31, |
|
Gross Profit |
|
|
|
|
|
Percent of |
|
|
|
|
|
|
Percent of |
|
|
Dollar |
|
|
Percentage |
|
(dollars in thousands) |
|
2009 |
|
|
Revenue |
|
|
2008 |
|
|
Revenue |
|
|
Change |
|
|
Change |
|
|
CAG |
|
$ |
96,442 |
|
|
|
49.8 |
% |
|
$ |
101,554 |
|
|
|
50.1 |
% |
|
$ |
(5,112 |
) |
|
|
(5.0 |
%) |
Water |
|
|
11,156 |
|
|
|
70.4 |
% |
|
|
10,315 |
|
|
|
61.3 |
% |
|
|
841 |
|
|
|
8.2 |
% |
PAS |
|
|
13,108 |
|
|
|
71.8 |
% |
|
|
14,233 |
|
|
|
67.3 |
% |
|
|
(1,125 |
) |
|
|
(7.9 |
%) |
Other |
|
|
3,548 |
|
|
|
41.0 |
% |
|
|
3,558 |
|
|
|
42.8 |
% |
|
|
(10 |
) |
|
|
(0.3 |
%) |
Unallocated amounts |
|
|
179 |
|
|
|
N/A |
|
|
|
176 |
|
|
|
N/A |
|
|
|
3 |
|
|
|
1.7 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Company |
|
$ |
124,433 |
|
|
|
52.6 |
% |
|
$ |
129,836 |
|
|
|
52.1 |
% |
|
$ |
(5,403 |
) |
|
|
(4.2 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
21
Companion Animal Group. Gross profit for CAG decreased due to overall lower sales volume and a
slight decrease in the gross profit percentage. The decrease in the gross profit percentage was due
primarily to higher
costs of instrument service relating to the larger installed base of IDEXX VetLab®
instruments and higher relative sales of lower margin laboratory and consulting services and IDEXX
VetLab® instruments. These unfavorable impacts were partly offset by the favorable impact of foreign
currency hedge contracts and the favorable currency impact of foreign currency denominated
expenses, net of the unfavorable impact that strengthening of the U.S. Dollar had on sales
denominated in foreign currencies, and the impact of higher selling prices.
Water. Gross profit for Water increased due to an increase in the gross profit percentage to
70% from 61%. The increase in the gross profit percentage was due primarily to the favorable impact
of foreign currency hedge contracts and the favorable currency impact of foreign currency
denominated expenses, net of the unfavorable impact that strengthening of the U.S. Dollar had on
sales denominated in foreign currencies. The gross profit percentage was also favorably impacted by
the non-recurrence of discrete costs incurred in the first quarter of 2008 in connection with a
discontinued project to qualify a second source supplier for certain products, by lower royalty
costs, and by higher average unit sales prices.
Production Animal Segment. Gross profit for PAS decreased due to lower sales volume, partly
offset by an increase in the gross profit percentage to 72% from 67%. The increase in the gross
profit percentage was due primarily to the favorable impact of foreign currency hedge contracts and
the favorable currency impact of foreign currency denominated expenses, net of the unfavorable
impact that strengthening of the U.S. Dollar had on sales denominated in foreign currencies and, to
a lesser extent, to higher relative sales of higher margin products, and to lower royalty costs.
These favorable items were partly offset by the impact of revenue recognized in 2008 on shipments
prior to January 1, 2008 to a customer for which we recognize revenue on the cash basis of
accounting due to uncertain collectibility.
Other. Gross profit for Other operating units decreased slightly as higher sales volumes were
predominantly offset by a decrease in the gross profit percentage to 41% from 43%. The decrease in
the gross profit percentage was due primarily to comparatively higher costs of production and
relatively higher sales of Dairy SNAP® antibiotic residue tests in geographies where the
products are sold at lower unit prices. These unfavorable impacts were partly offset by the
favorable impact of foreign currency hedge contracts and the favorable currency impact of foreign
currency denominated expenses, net of the unfavorable impact that strengthening of the U.S. Dollar
had on sales denominated in foreign currencies.
Operating Expenses and Operating Income
Total Company. The following tables present operating expenses and operating income by
operating segment:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended March 31, |
|
Operating Expenses |
|
|
|
|
|
Percent of |
|
|
|
|
|
|
Percent of |
|
|
Dollar |
|
|
Percentage |
|
(dollars in thousands) |
|
2009 |
|
|
Revenue |
|
|
2008 |
|
|
Revenue |
|
|
Change |
|
|
Change |
|
|
CAG |
|
$ |
67,363 |
|
|
|
34.8 |
% |
|
$ |
72,430 |
|
|
|
35.7 |
% |
|
$ |
(5,067 |
) |
|
|
(7.0 |
%) |
Water |
|
|
3,844 |
|
|
|
24.3 |
% |
|
|
4,045 |
|
|
|
24.1 |
% |
|
|
(201 |
) |
|
|
(5.0 |
%) |
PAS |
|
|
8,158 |
|
|
|
44.7 |
% |
|
|
8,405 |
|
|
|
39.7 |
% |
|
|
(247 |
) |
|
|
(2.9 |
%) |
Other |
|
|
3,419 |
|
|
|
39.5 |
% |
|
|
3,316 |
|
|
|
39.9 |
% |
|
|
103 |
|
|
|
3.1 |
% |
Unallocated amounts |
|
|
3,208 |
|
|
|
N/A |
|
|
|
2,921 |
|
|
|
N/A |
|
|
|
287 |
|
|
|
9.8 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Company |
|
$ |
85,992 |
|
|
|
36.4 |
% |
|
$ |
91,117 |
|
|
|
36.6 |
% |
|
$ |
(5,125 |
) |
|
|
(5.6 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating Income |
|
|
|
|
|
Percent of |
|
|
|
|
|
|
Percent of |
|
|
Dollar |
|
|
Percentage |
|
(dollars in thousands) |
|
2009 |
|
|
Revenue |
|
|
2008 |
|
|
Revenue |
|
|
Change |
|
|
Change |
|
|
CAG |
|
$ |
29,079 |
|
|
|
15.0 |
% |
|
$ |
29,124 |
|
|
|
14.4 |
% |
|
$ |
(45 |
) |
|
|
(0.2 |
%) |
Water |
|
|
7,312 |
|
|
|
46.1 |
% |
|
|
6,270 |
|
|
|
37.3 |
% |
|
|
1,042 |
|
|
|
16.6 |
% |
PAS |
|
|
4,950 |
|
|
|
27.1 |
% |
|
|
5,828 |
|
|
|
27.5 |
% |
|
|
(878 |
) |
|
|
(15.1 |
%) |
Other |
|
|
129 |
|
|
|
1.5 |
% |
|
|
242 |
|
|
|
2.9 |
% |
|
|
(113 |
) |
|
|
(46.7 |
%) |
Unallocated amounts |
|
|
(3,029 |
) |
|
|
N/A |
|
|
|
(2,745 |
) |
|
|
N/A |
|
|
|
(284 |
) |
|
|
(10.3 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Company |
|
$ |
38,441 |
|
|
|
16.3 |
% |
|
$ |
38,719 |
|
|
|
15.5 |
% |
|
$ |
(278 |
) |
|
|
(0.7 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22
Companion Animal Group. The following table presents CAG operating expenses by functional
area:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended March 31, |
|
Operating Expenses |
|
|
|
|
|
Percent of |
|
|
|
|
|
|
Percent of |
|
|
Dollar |
|
|
Percentage |
|
(dollars in thousands) |
|
2009 |
|
|
Revenue |
|
|
2008 |
|
|
Revenue |
|
|
Change |
|
|
Change |
|
|
Sales and marketing |
|
$ |
34,844 |
|
|
|
18.0 |
% |
|
$ |
37,299 |
|
|
|
18.4 |
% |
|
$ |
(2,455 |
) |
|
|
(6.6 |
%) |
General and administrative |
|
|
22,822 |
|
|
|
11.8 |
% |
|
|
23,888 |
|
|
|
11.8 |
% |
|
|
(1,066 |
) |
|
|
(4.5 |
%) |
Research and development |
|
|
9,697 |
|
|
|
5.0 |
% |
|
|
11,243 |
|
|
|
5.5 |
% |
|
|
(1,546 |
) |
|
|
(13.8 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
$ |
67,363 |
|
|
|
34.8 |
% |
|
$ |
72,430 |
|
|
|
35.7 |
% |
|
$ |
(5,067 |
) |
|
|
(7.0 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In the fourth quarter of 2008, we sold a substantial portion of our pharmaceutical assets and
product lines and restructured the remainder of this business. As a result, we have not incurred
meaningful expenses related to this business in the first quarter of 2009 and will not incur
meaningful expenses in the future. This impact on sales and marketing expense, general and
administrative expense and research and development expense is referred to in the following
operating expense analysis as the impact of the pharmaceutical transaction.
The decrease in sales and marketing expense resulted primarily from the favorable impacts of
exchange rates on foreign currency denominated expenses and from the pharmaceutical transaction
noted above. To a lesser extent, lower spending on sales commissions and marketing programs also
reduced sales and marketing expense. These decreases were partly offset by higher personnel costs
due, in part, to the addition of customer service, marketing and sales personnel. The decrease in
general and administrative expense resulted primarily from lower spending on corporate support
functions and lower personnel costs due, in part, to decreased personnel. The decrease in research
and development expense resulted primarily from a decrease in spending due to the pharmaceutical
transaction noted above and, to a lesser extent, decreased development spending related to our
recently launched chemistry analyzer, Catalyst Dx, which we began shipping to customers at the end
of the first quarter of 2008.
Water. The following table presents Water expenses by functional area:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended March 31, |
|
Operating Expenses |
|
|
|
|
|
Percent of |
|
|
|
|
|
|
Percent of |
|
|
Dollar |
|
|
Percentage |
|
(dollars in thousands) |
|
2009 |
|
|
Revenue |
|
|
2008 |
|
|
Revenue |
|
|
Change |
|
|
Change |
|
|
Sales and marketing |
|
$ |
1,746 |
|
|
|
11.0 |
% |
|
$ |
1,999 |
|
|
|
11.9 |
% |
|
$ |
(253 |
) |
|
|
(12.7 |
%) |
General and administrative |
|
|
1,477 |
|
|
|
9.3 |
% |
|
|
1,493 |
|
|
|
8.9 |
% |
|
|
(16 |
) |
|
|
(1.1 |
%) |
Research and development |
|
|
621 |
|
|
|
3.9 |
% |
|
|
553 |
|
|
|
3.3 |
% |
|
|
68 |
|
|
|
12.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
$ |
3,844 |
|
|
|
24.3 |
% |
|
$ |
4,045 |
|
|
|
24.1 |
% |
|
$ |
(201 |
) |
|
|
(5.0 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The decrease in sales and marketing expense resulted primarily from the impact of exchange
rates on foreign currency denominated expenses and, to a lesser extent, lower travel costs. The
decrease in general and administrative expense was the result of lower legal expenses. The increase
in research and development expense was due primarily to an increase in spending on research and
development supplies and materials.
Production Animal Segment. The following table presents PAS operating expenses by functional
area:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended March 31, |
|
Operating Expenses |
|
|
|
|
|
Percent of |
|
|
|
|
|
|
Percent of |
|
|
Dollar |
|
|
Percentage |
|
(dollars in thousands) |
|
2009 |
|
|
Revenue |
|
|
2008 |
|
|
Revenue |
|
|
Change |
|
|
Change |
|
|
Sales and marketing |
|
$ |
2,936 |
|
|
|
16.1 |
% |
|
$ |
3,398 |
|
|
|
16.1 |
% |
|
$ |
(462 |
) |
|
|
(13.6 |
%) |
General and administrative |
|
|
3,189 |
|
|
|
17.5 |
% |
|
|
3,126 |
|
|
|
14.8 |
% |
|
|
63 |
|
|
|
2.0 |
% |
Research and development |
|
|
2,033 |
|
|
|
11.1 |
% |
|
|
1,881 |
|
|
|
8.9 |
% |
|
|
152 |
|
|
|
8.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
$ |
8,158 |
|
|
|
44.7 |
% |
|
$ |
8,405 |
|
|
|
39.7 |
% |
|
$ |
(247 |
) |
|
|
(2.9 |
%) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The decrease in sales and marketing expense resulted primarily from lower personnel and
personnel-related costs associated with lower spending on commissions and lower personnel. To a
lesser extent, the favorable impact of exchange rates on foreign currency denominated expenses also
contributed to lower sales and marketing expense. The increase in general and administrative
expense resulted primarily from increased personnel costs, partly offset by lower bad debt expense
and reduced amortization expense related to intangible assets. The increase in research and
development expense resulted primarily from an increase in spending on third-party consulting firms
used to
conduct research and on research and development supplies, partly offset by the favorable
impact of exchange rates on foreign currency denominated expenses.
23
Other. Operating expenses for Other operating units increased $0.1 million to $3.4 million for
the three months ended March 31, 2009 due primarily to higher personnel costs.
Unallocated Amounts. Operating expenses that are not allocated to our operating segments
increased $0.3 million to $3.2 million for the three months ended March 31, 2009 due primarily to
the accrual of lease costs for a facility that we have vacated and not yet subleased.
Interest Income and Interest Expense
Interest income was $0.2 million and $0.5 million for the three months ended March 31, 2009
and 2008, respectively. Lower effective interest rates were partly offset by higher average
invested cash balances during the three months ended March 31, 2009 as compared to 2008.
Interest expense was $0.6 million and $1.0 million for the three months ended March 31, 2009
and 2008, respectively. Lower effective interest rates on outstanding debt balances were partly
offset by incremental borrowings under our revolving credit facility during the three months ended
March 31, 2009 as compared to 2008.
Provision for Income Taxes
Our effective income tax rates were 31.5% and 27.9% for the three months ended March 31, 2009
and 2008, respectively. The increase in the effective tax rate for the three months ended March 31,
2009 as compared to the three months ended March 31, 2008 relates primarily to a reduction in
international deferred tax liabilities in 2008 due to a change in the statutory tax rates for a
jurisdiction in which we operate. This non-recurring benefit of approximately $1.5 million reduced
our effective income tax rate for the three months ended March 31, 2008 by 3.9 percentage points.
The impact of the non-recurring item was partly offset by federal research and development tax
incentives that were available for the three months ended March 31, 2009 due to a change in the tax
law, but not available for the three months ended March 31, 2008.
Recent Accounting Pronouncements
A discussion of recent accounting pronouncements is included in Note 3(q) to the consolidated
financial statements included in our Annual Report on Form 10-K for the year ended December 31,
2008 and in Note 2 to the condensed consolidated financial statements included in this Quarterly
Report on Form 10-Q.
Liquidity and Capital Resources
Liquidity
We fund the capital needs of our business through cash on hand, funds generated from
operations, and amounts available under our unsecured short-term revolving credit facility (Credit
Facility). At March 31, 2009 and December 31, 2008, we had $86.3 million and $78.9 million,
respectively, of cash and cash equivalents, and working capital of $75.6 million and $60.6 million,
respectively. Additionally, at March 31, 2009, we had remaining borrowing availability under our
Credit Facility of $34.5 million. We believe that current cash and cash equivalents, funds
generated from operations, and amounts available under our Credit Facility will be sufficient to
fund our operations, capital purchase requirements, and strategic growth needs. We further believe
that we could obtain additional borrowings at prevailing market interest rates to fund our growth
objectives. However, based on the current credit market, we believe that the interest rates,
financial covenants and other terms of such borrowings would be less favorable than those
applicable to our current Credit Facility and those which otherwise would have been available
historically.
We consider the operating earnings of certain non-United States subsidiaries to be
indefinitely invested outside the U.S. Changes to this policy could have adverse tax consequences.
Subject to this policy, we manage our worldwide cash requirements considering available funds among
all of our subsidiaries. Our foreign cash balances are generally available without legal
restrictions to fund ordinary business operations outside the U.S.
24
The following table presents additional key information concerning working capital:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Three Months Ended |
|
|
|
March 31, |
|
|
December 31, |
|
|
September 30, |
|
|
June 30, |
|
|
March 31, |
|
|
|
2009 |
|
|
2008 |
|
|
2008 |
|
|
2008 |
|
|
2008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Days sales outstanding |
|
|
43.8 |
|
|
|
41.9 |
|
|
|
42.3 |
|
|
|
39.9 |
|
|
|
42.6 |
|
Inventory turns |
|
|
1.6 |
|
|
|
2.0 |
|
|
|
1.9 |
|
|
|
2.1 |
|
|
|
2.0 |
|
Sources and Uses of Cash
Cash provided by operating activities was $12.6 million for the three months ended March 31,
2009, compared to cash used of $2.8 million for the same period in 2008. We historically have
experienced proportionally lower or net negative cash flows from operating activities during the
first quarter and proportionally higher or net positive cash flows from operating activities for
the remainder of the year and for the annual period. Several factors contribute to the seasonal
fluctuations in cash flows generated by operating activities, including the following:
|
|
|
Accounts receivable are historically higher in the first quarter of the year due to
seasonality of certain products. |
|
|
|
|
We have management and non-management employee incentive programs that provide for
the payment of annual bonuses in the first quarter following the year for which the
bonuses were earned. |
|
|
|
|
We have agreements with certain suppliers that require us to make minimum annual
inventory purchases, in some cases in order to retain exclusive distribution rights,
and we have other agreements with suppliers that provide for lower pricing based on
annual purchase volumes. We may place a higher volume of purchase orders for inventory
during the fourth quarter in order to meet our minimum commitments or realize volume
pricing discounts and we receive that inventory in the fourth or first quarters and pay
in the first quarter. The specific facts and circumstances that we consider in
determining the timing and level of inventory purchases throughout the year related to
these agreements may yield inconsistent cash flows from operations, most typically in
the first and fourth quarters. |
The total of net income and net non-cash charges was $43.5 million for the three months ended
March 31, 2009, compared to $38.8 million for the same period in 2008. During the three months
ended March 31, 2009, cash decreased by $30.9 million due to changes in operating assets and
liabilities, compared to a decrease in the same period of 2008 of $41.6 million, resulting in a
year-to-year increase in cash of $10.7 million. The decrease in cash used by changes in operating
assets and liabilities, compared to 2008, was primarily attributable to $10.0 million incremental
cash provided by a smaller reduction in accrued expenses and accounts payable and $7.5 million less
cash used to generate changes in accounts receivable. These increases in cash were partly offset by
an incremental decrease in cash of $7.6 million caused by increases in inventories. The incremental
cash provided by changes in accrued expenses was due primarily to the timing of tax payments made
in 2008 as compared to 2009.
An unusually high balance of VetTest® slide inventory existed at the end of the
fourth quarter of 2007 due to the timing of receipts of shipments. This in turn resulted in an
unusually high accounts payable balance due to our supplier of these slides. This payable was paid
in the first quarter of 2008 and the accounts payable balance returned to normal levels by the end
of the first quarter of 2008. This large payment drove a higher amount of cash used by accounts
payable in the first three months of 2008 as compared to the same period of 2009. The unusually
high balance of VetTest® slide inventory at the end of 2007 also normalized by the end
of the first quarter of 2008, which drove less cash used to purchase inventory in the first quarter
of 2008 as compared to the first quarter of 2009. The incremental cash provided by decreases in
accounts receivable was due to slower sales growth in the first three months of 2009 compared to
the same period of the prior year.
Cash used by investing activities was $6.9 million for the three months ended March 31, 2009,
compared to cash used of $24.8 million for the same period of 2008. The decrease in cash used by
investing activities for 2009, compared to 2008, was due primarily to $7.9 million less cash used
for purchases of property and equipment, and $7.5 million less cash used for business acquisitions
and purchases of other assets not comprising businesses.
The decrease in purchases of property and equipment was primarily attributable to lower
spending on the renovation and expansion of our headquarters facility in Westbrook, Maine. We paid
$9.1 million to purchase fixed
assets during the three months ended March 31, 2009. Our total capital expenditure plan for
2009 is approximately $55 million, which includes approximately $24 million for the renovation and
expansion of our headquarters facility.
25
We did not enter into any acquisition-related transactions during the three months ended March
31, 2009. We paid $6.8 million and assumed liabilities of $0.1 million to acquire businesses and
certain intangible assets that did not comprise businesses during the three months ended March 31,
2008. We also made purchase price payments of $0.7 million related to the achievement of milestones
achieved by certain businesses acquired in prior years.
At March 31, 2009 we had $165.5 million outstanding under our Credit Facility, of which $6.5
million was borrowed by our Canadian subsidiary and denominated in Canadian dollars. The applicable
interest rates on the Credit Facility generally range from 0.375 to 0.875 percentage points above
the London interbank rate (LIBOR) or the Canadian Dollar-denominated bankers acceptance rate
(CDOR), dependent on our leverage ratio. Under the Credit Facility, we pay quarterly commitment
fees of 0.08% to 0.20%, dependent on our leverage ratio, on any unused commitment. The Credit
Facility contains financial and other affirmative and negative covenants, as well as customary
events of default, that would allow any amounts outstanding under the Credit Facility to be
accelerated, or restrict our ability to borrow thereunder, in the event of noncompliance. The
financial covenant requires our ratio of debt to earnings before interest, taxes, depreciation and
amortization, as defined by the agreement, not to exceed 3-to-1. At March 31, 2009 we were in
compliance with the covenants of the Credit Facility. Compared to March 31, 2008, the total amount
outstanding under our Credit Facility had increased $25.6 million. Cash received from borrowings
was primarily used to repurchase shares of our common stock.
Our board of directors has authorized the repurchase of up to 40,000,000 shares of our common
stock in the open market or in negotiated transactions. From the inception of the program in August
1999 to March 31, 2009, we repurchased 36,255,000 shares. Cash used to repurchase shares during the
three months ended March 31, 2009 and 2008 was $15.0 million and $51.4 million, respectively. We
believe that the repurchase of our common stock is a favorable investment and we also repurchase to
offset the dilutive effect of our share-based compensation programs. Repurchases of our common
stock may vary depending upon the level of other investing activities and the share price. See Note
13 to the condensed consolidated financial statements included in this Quarterly Report on Form
10-Q for additional information about our share repurchases.
Other Commitments, Contingencies and Guarantees
Significant commitments, contingencies and guarantees at March 31, 2009 are consistent with
those discussed in the section captioned Managements Discussion and Analysis of Financial
Condition and Results of OperationsLiquidity and Capital Resources, and in Note 12 to the
consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31,
2008.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Our financial market risk consists primarily of foreign currency exchange rate risk and
interest rate risk. Our functional currency is the U.S. dollar and our primary manufacturing
operations are in the U.S., but we distribute our products worldwide both through direct export and
through our subsidiaries. Our primary foreign currency transaction risk consists of intercompany
sales of product and we attempt to mitigate this risk through our hedging program described below.
For the three months ended March 31, 2009, approximately 23% of our revenues were derived from
products manufactured in the U.S. and sold internationally. Our subsidiaries in 17 foreign
countries use the local currency as their functional currency.
The primary purpose of our foreign currency hedging activities is to protect against the
volatility associated with foreign currency transactions. We also utilize natural hedges to
mitigate our transaction and commitment exposures. Our corporate policy prescribes the range of
allowable hedging activity. We enter into exchange contracts with large multinational financial
institutions and we do not hold or engage in transactions involving derivative instruments for
purposes other than risk management. Our accounting policies for these contracts are based on our
designation of such instruments as hedging transactions. Market gains and losses are deferred in
other current or long-term assets or accruals, as appropriate, until the contract matures, which is the period
when the related obligation is settled. We primarily utilize forward exchange contracts with
durations of less than 21 months.
Our subsidiaries enter into foreign currency exchange contracts to minimize the impact of
foreign currency fluctuations associated with their anticipated intercompany inventory purchases
for the next year. From time to time,
we may also enter into foreign currency exchange contracts to minimize the impact of foreign
currency fluctuations associated with specific, significant transactions.
26
We identify foreign currency exchange risk by regularly monitoring our transactions
denominated in foreign currencies. We attempt to mitigate currency risk by hedging the majority of
our cash flow on intercompany sales to minimize foreign currency exposure. Currency exposure on
large purchases of foreign currency denominated products are evaluated in our hedging program and
used as natural hedges to offset identified hedge requirements related to intercompany sales.
Our hedging strategy is consistent with prior periods and there were no material changes in
our market risk exposure during the three months ended March 31, 2009. We enter into forward
currency exchange contracts designated as cash flow hedges for amounts that are less than the full
value of forecasted intercompany sales and for amounts that are equivalent to, or less than, other
specific, significant transactions, thus no significant ineffectiveness has resulted or been
recorded through the statements of operations. Our hedging strategy related to intercompany
inventory purchases is to employ the full amount of our hedges for the following year at the
conclusion of our budgeting process, which is complete by the end of the year. Quarterly, we enter
into contracts to hedge incremental portions of anticipated foreign currency transactions for the
following year that are in excess of amounts previously hedged. Accordingly, our risk with respect
to foreign currency exchange rate fluctuations may vary throughout each annual cycle.
We enter into hedge agreements where we believe we have meaningful exposure to foreign
currency exchange risk. The notional amount of foreign currency contracts to hedge forecasted
intercompany sales outstanding at March 31, 2009 and 2008 was $118.1 million and $102.8 million,
respectively. At March 31, 2009, we had $5.6 million in net unrealized gains on foreign exchange
contracts designated as hedges recorded in other comprehensive income, which is net of $2.5 million
in taxes.
We are subject to interest rate risk based on the terms of our Credit Facility to the extent
that the LIBOR increases or the CDOR increases. Borrowings under our Credit Facility bear interest
in the range from 0.375 to 0.875 percentage points (Credit Spread) above the LIBOR or the CDOR,
dependent on our consolidated leverage ratio, and the interest period terms for the outstanding
borrowings, which range from one to six months. As discussed below, we have entered into forward
fixed interest rate swaps to mitigate interest rate risk in future periods commencing March 31,
2010. Borrowings outstanding at March 31, 2009 were $165.5 million at a weighted-average interest
rate of 1.1%. An increase in the LIBOR or the CDOR of 1% would increase interest expense by
approximately $1.7 million annually.
In March 2009, we entered into two forward fixed interest rate swap agreements for an
aggregate notional amount of $80 million to manage the economic effect of variable interest
obligations on amounts borrowed under the terms of our Credit Facility. Under these agreements, we
will effectively fix our interest exposure on $80 million of our outstanding borrowings for the
period commencing March 31, 2010, through March 30, 2012 by converting our variable interest rate
payments to fixed interest rate payments at 2% plus the Credit Spread. The critical terms of the
fixed interest rate swap agreements match the critical terms of the underlying borrowings,
including notional amounts, underlying market indices, interest rate reset dates and maturity
dates. Accordingly, we have designated these swaps as qualifying instruments to be accounted for as
cash flow hedges pursuant to SFAS No. 133, Accounting for Derivative Instruments and Hedging
Activities. See Note 16 to the condensed consolidated financial statements included in this
Quarterly Report on Form 10-Q for a discussion of our derivative instruments and hedging
activities.
For quantitative and qualitative disclosures about market risk affecting IDEXX, see Item 7A,
Quantitative and Qualitative Disclosures About Market Risk of our Annual Report on Form 10-K for
the fiscal year ended December 31, 2008. As of the date of this report, there have been no material
changes to the market risks described in our Annual Report on Form 10-K for December 31, 2008.
27
Item 4. Controls and Procedures
Disclosure Controls and Procedures
Our management is responsible for establishing and maintaining disclosure controls and
procedures, as defined by the SEC in its Rules 13a-15(e) and 15d-15(e) under the Securities
Exchange Act of 1934 as amended (the Exchange Act). The term disclosure controls and
procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and
other procedures of a company that are designed to ensure that information required to be disclosed
by the company in the reports that it files or submits under the Exchange Act is recorded,
processed, summarized and reported, within the time periods specified in the SECs rules and forms.
Disclosure controls and procedures include, without limitation, controls and procedures designed to
ensure that information required to be disclosed by a company in the reports that it files or
submits under the Exchange Act is accumulated and communicated to the companys management,
including its principal executive and principal financial officers, as appropriate to allow timely
decisions regarding required disclosure. Management recognizes that any controls and procedures, no
matter how well designed and operated, can provide only reasonable assurance of achieving their
objectives and management necessarily applies its judgment in evaluating the cost-benefit
relationship of possible controls and procedures. Based on the evaluation of our disclosure
controls and procedures at March 31, 2009, our chief executive officer and chief financial officer
have concluded that, as of the end of the period covered by this report, our disclosure controls
and procedures are effective to achieve their stated purpose.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rules
13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended March 31, 2009 that
materially affected, or are reasonably likely to materially affect, the Companys internal control
over financial reporting.
PART II OTHER INFORMATION
Item 1. Legal Proceedings
On June 30, 2006, Cyntegra, Inc. filed suit against us in the U.S. District Court for the
Central District of California alleging that we had violated U.S. federal antitrust laws and
California state unfair trade practices laws. The complaint alleged, among other things, that we
were monopolizing the U.S. market for companion animal diagnostic products. The plaintiff sought
injunctive relief and damages for purported lost sales. On October 26, 2007, the trial court
granted summary judgment in our favor on all of Cyntegras claims and dismissed the suit. Cyntegra
appealed this decision to the U.S. Court of Appeals for the Ninth Circuit. Cyntegra filed its
opening brief on appeal on May 30, 2008; we filed our opposition brief on July 2, 2008; and
Cyntegra filed its reply brief on July 16, 2008. Oral argument before the Court of Appeals was held
on April 13, 2009. We anticipate a decision from the Appeals Court during the second quarter of
2009. Until then, the trial court judgment in our favor remains in place. We will continue to
defend ourselves vigorously, as we believe Cyntegras claims are without merit.
From time to time, we are subject to other legal proceedings and claims, which arise in the
ordinary course of business. In the opinion of management, the ultimate disposition of these
matters will not have a material adverse effect on our results of operations, financial condition
or cash flows.
Item 1A. Risk Factors
Our future operating results involve a number of risks and uncertainties. Actual events or
results may differ materially from those discussed in this report. Factors that could cause or
contribute to such differences include, but are not limited to, the factors discussed below, as
well as those discussed elsewhere in this report.
Our Failure to Successfully Execute Certain Strategies Could Have a Negative Impact on Our
Growth and Profitability
The companion animal health care industry is very competitive and we anticipate increased
competition from both existing competitors and new market entrants. Our ability to maintain or
enhance our historical growth rates and our profitability depends on our successful execution of
many elements of our strategy, which include:
|
|
|
Developing, manufacturing and marketing innovative new in-house laboratory analyzers
such as Catalyst Dx and SNAPshot Dx® that drive sales of IDEXX
VetLab® instruments, grow our installed base of instruments, and create a
recurring revenue stream from consumable products; |
|
|
|
|
Developing and introducing new proprietary diagnostic tests and services that
effectively differentiate our products and services from those of our competitors; |
28
|
|
|
Achieving the benefits of economies of scale in our worldwide reference laboratory
business; |
|
|
|
|
Increasing the value to our customers of our companion animal products and services
by enhancing the integration of these products; |
|
|
|
|
Growing our market share by strengthening our sales and marketing activities both
within the U.S. and in geographies outside of the U.S.; and |
|
|
|
|
Developing and implementing new technology and licensing strategies; and
identifying, completing and integrating acquisitions that enhance our existing
businesses or create new business or geographic areas for us. |
If we are unsuccessful in implementing some or all of these strategies, our rate of growth or
profitability may be negatively impacted.
A Weak Economy Could Result in Reduced Demand for Our Products and Services
A substantial percentage of our sales are made worldwide to the companion animal veterinary
market. Demand for our companion animal diagnostic products and services is driven in part by the
number of pet visits to veterinary hospitals and the practices of veterinarians with respect to
diagnostic testing. Economic weakness in our significant markets could cause pet owners to skip or
defer visits to veterinary hospitals or could affect their willingness to treat certain pet health
conditions, approve certain diagnostic tests, or continue to own a pet. In addition, concerns about
the financial resources of pet owners could cause veterinarians to be less likely to recommend
certain diagnostic tests. A decline in pet visits to the hospital, in the willingness of pet owners
to treat certain health conditions or approve certain tests, in pet ownership, or in the
inclination of veterinarians to recommend certain tests could result in a decrease in diagnostic
testing, and therefore in our sales of diagnostic products and services.
Disruption in Financial and Currency Markets Could Have a Negative Effect on Our Business
As widely reported, financial markets in the U.S., Europe and Asia have been experiencing
extreme disruption in recent months, including, among other things, extreme volatility in exchange
rates and security prices, severely diminished liquidity and credit availability, rating downgrades
of certain investments and declining valuations of others. These economic developments affect
businesses such as ours in a number of ways. The current tightening of credit in financial markets
may adversely affect the ability of customers to obtain financing for significant purchases and
operations and could result in a decrease in orders for our products and services. The inability of
pet owners to obtain consumer credit could lead to a decline in pet visits to the veterinarian,
which could result in a decrease in diagnostic testing. Likewise, a decrease in diagnostic testing
could negatively impact the financial condition of the veterinary practices that are our customers,
which may inhibit their ability to pay us amounts owed for products delivered or services provided.
In addition, although current economic conditions have not impacted our ability to access credit
markets and finance our operations, further deterioration in financial markets could adversely
affect our access to capital. We are unable to predict the likely duration and severity of the
current disruption in financial markets and adverse economic conditions in the U.S. and other
countries.
Strengthening of the Rate of Exchange for the U.S. Dollar Has a Negative Effect on Our
Business
Strengthening of the rate of exchange for the U.S. Dollar against the Euro, the British Pound,
the Canadian Dollar, the Japanese Yen and the Australian Dollar adversely affects our results, as
it reduces the dollar value of sales that are made in those currencies and reduces the margins on
products manufactured in the U.S. and exported to international markets. For the three months ended
March 31, 2009 approximately 23% of IDEXX sales were a result of exports from the U.S.
29
Our Dependence on a Limited Number of Suppliers Could Limit Our Ability to Sell Certain
Products or Reduce Our Profitability
We currently purchase many products and materials from single sources or a limited number of
sources. Some of the products that we purchase from these sources are proprietary, and, therefore,
cannot be readily or easily replaced by alternative sources. These products include our
VetAutoread hematology, VetLyte® electrolyte, IDEXX VetLab® UA urinalysis,
VetTest® chemistry, and Coag Dx blood coagulation analyzers and related consumables and
accessories; image capture plates used in our digital radiography systems; and certain components
and raw materials used in our SNAP® rapid assay devices, water testing products and
LaserCyte® hematology analyzers. If we are unable to obtain adequate quantities of these
products in the future, we could face cost increases or reductions, delays or discontinuations in
product shipments, which could result in our inability to supply the market, which would have a
material adverse effect on our results of operations.
Our Biologic Products Are Complex and Difficult to Manufacture, Which Could Negatively
Affect Our Ability to Supply the Market
Many of our rapid assay and production animal diagnostic products are biologics, which are
products that are comprised of materials from living organisms, such as antibodies, cells and sera.
Manufacturing biologic products is highly complex. Unlike products that rely on chemicals for
efficacy (such as most pharmaceuticals), biologics are difficult to characterize due to the
inherent variability of biological input materials. Difficulty in characterizing biological
materials or their interactions creates greater risk in the manufacturing process. There can be no
assurance that we will be able to maintain adequate sources of biological materials or that
biological materials that we maintain in inventory will yield finished products that satisfy
applicable product release criteria. Our inability to produce or obtain necessary biological
materials or to successfully manufacture biologic products that incorporate such materials could
result in our inability to supply the market with these products, which could have a material
adverse effect on our results of operations.
Various Government Regulations Could Limit or Delay Our Ability to Market and Sell Our
Products
In the U.S., the manufacture and sale of our products are regulated by agencies such as the
United States Department of Agriculture (USDA), the U.S. Food and Drug Administration (FDA) and
the U.S. Environmental Protection Agency (EPA). Most diagnostic tests for animal health
applications, including our canine, feline, poultry and livestock tests, must be approved by the
USDA prior to sale in the U.S. Our water testing products must be approved by the EPA before they
can be used by customers in the U.S. as a part of a water quality monitoring program required by
the EPA. Our dairy testing products require approval by the FDA. The manufacture and sale of our
OPTI® line of human point-of-care electrolytes and blood gas analyzers are regulated by
the FDA and these products require approval by the FDA before they may be sold commercially in the
U.S. The manufacture and sale of our products are subject to similar laws in many foreign
countries. Any failure to comply with legal and regulatory requirements relating to the manufacture
and sale of our products in the U.S. or in other countries could result in fines and sanctions
against us or removals of our products from the market, which could have a material adverse effect
on our results of operations. In addition, delays in obtaining regulatory approvals for new
products or product upgrades could have a negative impact on our growth and profitability.
Our Success Is Heavily Dependent Upon Our Proprietary Technologies
We rely on a combination of patent, trade secret, trademark and copyright laws to protect our
proprietary rights. If we do not have adequate protection of our proprietary rights, our business
may be affected by competitors who utilize substantially equivalent technologies that compete with
us.
We cannot ensure that we will obtain issued patents, that any patents issued or licensed to us
will remain valid, or that any patents owned or licensed by us will provide protection against
competitors with similar technologies. Even if our patents cover products sold by our competitors,
the time and expense of litigating to enforce our patent rights could be substantial, and could
have a material adverse effect on our results of operations. In addition, expiration of patent
rights could result in substantial new competition in the markets for products previously covered
by those patent rights. In this regard, we expect that revenues and profit margins associated with
sales of our SNAP® FIV/FeLV tests are likely to decline following the expiration in June
2009 of a U.S. patent that we exclusively license that broadly covers products that diagnose feline
immunodeficiency virus.
30
In the past, we have received notices claiming that our products infringe third-party patents
and we may receive such notices in the future. Patent litigation is complex and expensive, and the
outcome of patent litigation can be difficult to predict. We cannot ensure that we will win a
patent litigation case or negotiate an acceptable resolution of such a case. If we lose, we may be
stopped from selling certain products and/or we may be required to pay damages and/or ongoing
royalties as a result of the lawsuit. Any such adverse result could have a material adverse effect
on our results of operations.
Distributor Purchasing Patterns Could Negatively Affect Our Operating Results
We sell many of our products, including substantially all of the rapid assays and instrument
consumables sold in the U.S., through distributors. Distributor purchasing patterns can be
unpredictable and may be influenced by factors unrelated to the end-user demand for our products.
In addition, our agreements with distributors may generally be terminated by the distributors for
any reason on 60 days notice. Because significant product sales are made to a limited number of
distributors, the loss of a distributor or unanticipated changes in the frequency, timing or size
of distributor purchases, could have a negative effect on our results of operations.
Distributors of veterinary products have entered into business combinations resulting in fewer
distribution companies. Consolidation within distribution channels would increase our customer
concentration level, which could increase the risks described in the preceding paragraph.
Increased Competition and Technological Advances by Our Competitors Could Negatively Affect
Our Operating Results
We face intense competition within the markets in which we sell our products and services. We
expect that future competition will become even more intense, and that we will have to compete with
changing and improving technologies. Competitors may develop products that are superior to our
products, and as a result, we may lose existing customers and market share. Some of our competitors
and potential competitors, including large diagnostic companies, have substantially greater
financial resources than us, and greater experience in manufacturing, marketing, research and
development and obtaining regulatory approvals than we do.
Changes in Testing Patterns Could Negatively Affect Our Operating Results
The market for our companion and production animal diagnostic tests and our dairy and water
testing products could be negatively impacted by a number of factors. The introduction or broad
market acceptance of vaccines or preventatives for the diseases and conditions for which we sell
diagnostic tests and services could result in a decline in testing. Changes in accepted medical
protocols regarding the diagnosis of certain diseases and conditions could have a similar effect.
Eradication or substantial declines in the prevalence of certain diseases also could lead to a
decline in diagnostic testing for such diseases. Our production animal products business in
particular is subject to fluctuations resulting from changes in disease prevalence. In addition,
changes in government regulations could negatively affect sales of our products that are driven by
compliance testing, such as our production animal, dairy and water products. Declines in testing
for any of the reasons described could have a material adverse effect on our results of operations.
Effective January 1, 2009, testing of water supplies for Cryptosporidium is no longer required
by regulation in England or Wales. Our customers in these countries may voluntarily continue to
test for Cryptosporidium and we have not seen a significant decrease in testing in the first
quarter of 2009. However, we may lose sales of Filta-Max® products in the future to
customers in England and Wales who have tested solely based on regulatory requirements. Our sales
of Filta-Max® products in England and Wales were $0.5 million for the three months ended
March 31, 2009.
Effective January 1, 2009, the age at which healthy cattle to be slaughtered are required to
be tested for bovine spongiform encephalopathy (BSE) in the European Union was increased from 30
months to 48 months, which has been estimated to reduce the population of cattle tested by
approximately 30%. As a result, we believe that we are likely to lose a portion of our sales of
post-mortem test for BSE.
31
Consolidation of Veterinary Hospitals Could Negatively Affect Our Business
An increasing percentage of veterinary hospitals in the U.S. is owned by corporations that are
in the business of acquiring veterinary hospitals and/or opening new veterinary hospitals
nationally or regionally. Major
corporate hospital owners in the U.S. include VCA Antech, Inc., National Veterinary
Associates, and Banfield, The Pet Hospital, each of which is currently a customer of IDEXX. A
similar trend exists in the U.K. and may in the future also develop in other countries. Corporate
owners of veterinary hospitals could attempt to improve profitability by leveraging the buying
power they derive from their scale to obtain favorable pricing from suppliers, which could have a
negative impact on our results. In addition, certain corporate owners, most notably VCA Antech, our
primary competitor in the U.S. and Canadian markets for reference laboratory services, also operate
reference laboratories that serve both their hospitals and unaffiliated hospitals. Any hospitals
acquired by these companies are likely to use their laboratory services almost exclusively. In
addition, because these companies compete with us in the laboratory services business, hospitals
acquired by these companies may cease to be customers or potential customers of our other companion
animal products and services, which would cause our sales of these products and services to
decline.
Our Inexperience in the Human Point-of-Care Market Could Inhibit Our Success in this Market
Upon acquiring the Critical Care Division of Osmetech plc in January 2007, we entered the
human point-of-care medical diagnostics market for the first time with the sale of the
OPTI® line of electrolyte and blood gas analyzers. The human point-of-care medical
diagnostics market differs in many respects from the veterinary medical market. Significant
differences include the impact of third party reimbursement on diagnostic testing, more extensive
regulation, greater product liability risks, larger competitors, a more segmented customer base,
and more rapid technological innovation. Our inexperience in the human point-of-care medical
diagnostics market could negatively affect our ability to successfully manage the risks and
features of this market that differ from the veterinary medical market. There can be no assurance
that we will be successful in achieving growth and profitability in the human point-of-care medical
diagnostics market comparable to the results we have achieved in the veterinary medical market.
Risks Associated with Doing Business Internationally Could Negatively Affect Our Operating
Results
For the three months ended March 31, 2009, 38% of our revenue was attributable to sales of
products and services to customers outside the U.S. Various risks associated with foreign
operations may impact our international sales. Possible risks include fluctuations in the value of
foreign currencies, disruptions in transportation of our products, the differing product and
service needs of foreign customers, difficulties in building and managing foreign operations,
import/export duties and licensing requirements, and unexpected regulatory, economic or political
changes in foreign markets. Prices that we charge to foreign customers may be different than the
prices we charge for the same products in the U.S. due to competitive, market or other factors. As
a result, the mix of domestic and international sales in a particular period could have a material
impact on our results for that period. In addition, many of the products for which our selling
price may be denominated in foreign currencies are manufactured, sourced, or both, in the U.S. and
our costs are incurred in U.S. dollars. We utilize non-speculative forward currency exchange
contracts and natural hedges to mitigate foreign currency exposure. However, an appreciation of the
U.S. dollar relative to the foreign currencies in which we sell these products would reduce our
operating margins. Additionally, a strengthening U.S. dollar could negatively impact the ability of
customers outside the U.S. to pay for purchases denominated in U.S. dollars.
The Loss of Our President, Chief Executive Officer and Chairman Could Adversely Affect Our
Business
We rely on the management and leadership of Jonathan W. Ayers, our President, Chief Executive
Officer and Chairman. We do not maintain key man life insurance coverage for Mr. Ayers. The loss of
Mr. Ayers could have a material adverse impact on our business.
We Could Be Subject to Class Action Litigation Due to Stock Price Volatility, which, if it
Occurs, Could Result in Substantial Costs or Large Judgments Against Us
The market for our common stock may experience extreme price and volume fluctuations, which
may be unrelated or disproportionate to our operating performance or prospects. In the past,
securities class action litigation has often been brought against companies following periods of
volatility in the market prices of their securities. We may be the target of similar litigation in
the future. Securities litigation could result in substantial costs and divert our managements
attention and resources, which could have a negative effect on our business, operating results and
financial condition.
32
If Our Quarterly or Annual Results of Operations Fluctuate, This Fluctuation May Cause Our
Stock Price to Decline, Resulting in Losses to You
Our prior operating results have fluctuated due to a number of factors, including seasonality
of certain product lines; changes in our accounting estimates; the impact of acquisitions; timing
of distributor purchases, product launches, operating expenditures, litigation and claim-related
expenditures; changes in competitors product offerings; changes in the economy affecting consumer
spending; and other matters. Similarly, our future operating results may vary significantly from
quarter to quarter or year to year due to these and other factors, many of which are beyond our
control. If our operating results or projections of future operating results do not meet the
expectations of market analysts or investors in future periods, our stock price may fall.
Future Operating Results Could Be Negatively Affected by the Resolution of Various Uncertain
Tax Positions and by Potential Changes to Tax Incentives
In the ordinary course of our business, there are many transactions and calculations where the
ultimate tax determination is uncertain. Significant judgment is required in determining our
worldwide provision for income taxes. We periodically assess our exposures related to our worldwide
provision for income taxes and believe that we have appropriately accrued taxes for contingencies.
Any reduction of these contingent liabilities or additional assessment would increase or decrease
income, respectively, in the period such determination was made. Our income tax filings are
regularly under audit by tax authorities and the final determination of tax audits could be
materially different than that which is reflected in historical income tax provisions and accruals.
Additionally, we benefit from certain tax incentives offered by various jurisdictions. If we are
unable to meet the requirements of such incentives, our inability to use these benefits could have
a material negative effect on future earnings.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
During the three months ended March 31, 2009, we repurchased common shares as described below:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Number of |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares Purchased as |
|
|
Maximum Number of |
|
|
|
|
|
|
|
|
|
|
|
Part of Publicly |
|
|
Shares that May Yet Be |
|
|
|
Total Number of |
|
|
Average Price |
|
|
Announced Plans or |
|
|
Purchased Under the |
|
|
|
Shares Purchased |
|
|
Paid per Share |
|
|
Programs |
|
|
Plans or Programs |
|
Period |
|
(a) |
|
|
(b) |
|
|
(c) |
|
|
(d) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
January 1 to January 31, 2009 |
|
|
190,152 |
|
|
$ |
31.50 |
|
|
|
190,152 |
|
|
|
4,022,512 |
|
February 1 to February 28, 2009 |
|
|
182,886 |
|
|
|
33.31 |
|
|
|
151,800 |
|
|
|
3,870,712 |
|
March 1 to March 31, 2009 |
|
|
125,697 |
|
|
|
31.64 |
|
|
|
125,575 |
|
|
|
3,745,137 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
498,735 |
|
|
$ |
32.20 |
|
|
|
467,527 |
|
|
|
3,745,137 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Our board of directors has approved the repurchase of up to 40,000,000 shares of our common
stock in the open market or in negotiated transactions. The plan was approved and announced on
August 13, 1999, and subsequently amended on October 4, 1999, November 16, 1999, July 21, 2000,
October 20, 2003, October 12, 2004, October 12, 2005, February 14, 2007, and February 13, 2008 and
does not have a specified expiration date. There were no other repurchase plans outstanding during
the three months ended March 31, 2009, and no repurchase plans expired during the period.
Repurchases of 467,527 shares were made during the three months ended March 31, 2009 in open market
transactions.
During the three months ended March 31, 2009, we received 31,208 shares of our common stock
that were surrendered by employees in payment for the minimum required withholding taxes due on the
vesting of restricted stock units and settlement of deferred stock units. In the above table, these
shares are included in columns (a) and (b), but excluded from columns (c) and (d). These shares do
not reduce the number of shares that may yet be purchased under the repurchase plan.
33
Item 6. Exhibits
(a) Exhibits
|
|
|
|
|
|
31.1 |
|
|
Certification by Chief Executive Officer. |
|
|
|
|
|
|
31.2 |
|
|
Certification by Corporate Vice President, Chief Financial Officer and Treasurer. |
|
|
|
|
|
|
32.1 |
|
|
Certification by Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
|
|
|
|
|
32.2 |
|
|
Certification by Corporate Vice President, Chief Financial Officer and Treasurer
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002. |
34
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
IDEXX LABORATORIES, INC.
|
|
Date: April 24, 2009 |
/s/ Merilee Raines
|
|
|
Merilee Raines |
|
|
Corporate Vice President,
Chief Financial Officer and
Treasurer (Principal Financial Officer) |
|
35
Exhibit Index
|
|
|
|
|
Exhibit No. |
|
Description |
|
|
|
|
|
|
31.1 |
|
|
Certification by Chief Executive Officer. |
|
|
|
|
|
|
31.2 |
|
|
Certification by Corporate Vice President, Chief Financial Officer and Treasurer. |
|
|
|
|
|
|
32.1 |
|
|
Certification by Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. |
|
|
|
|
|
|
32.2 |
|
|
Certification by Corporate Vice President, Chief Financial Officer and Treasurer
pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002. |
36